COMMITTEES

Honorary Presidents
C. Black, F. Wollheim, T. Medsger

Steering Committee
D.E. Furst, L. Guillevin, T. Krieg, M. Kuwana, M. Matucci-Cerinic,
U. Mueller-Ladner, J. Seibold, K. Takehara, and the following
Chairpersons:
1. Chairpersons of the Abstract Committee:
O. Distler, P. Sampaio Barros
2. Chairpersons of the Clinical Committee:
Y. Allanore, D. Khanna
3. Chairpersons of the Basic Science Committee:
J. Distler, R. Lafyatis, J. Varga
4. Chairperson of the Workshops:
P. Clements
5. Liaison officer with the Scleroderma Workshop:
C. Denton, R. Lafyatis
6. Chairpersons of the Mentoring Programme:
L. Czirjak, M. Mayes

Scientific Committee
D. Abraham, L. Ananieva, Y. Asano, S. Assassi, A. Balbir-Gurmann,
M. Baron, P. Carreira, L. Catoggio, C. Chizzolini, M. Cutolo,
N. Damjanov, F. Del Galdo, J. Distler, C. Feghali-Botswick,
A. Gabrielli, S. Gay, E. Hachulla, A. Herrick, R. Hesselstrand, H. Ihn,
M. Inanc, S. Johnson, B. Kahaleh, Y. Kawaguchi, R. Knobler,
O. Kowal-Bielecka, T. Krieg, M.T. Li, P. Merkel, J. Pope,
M. Proudman, G. Riemekasten, S. Sato, R. Silver, R. Simms,
V. Steen, F. van den Hoogen, J. van Laar, M. Vonk, U. Walker,
A. Wells, F. Wigley, Y. Yamada

FESCA Board
Annelise Roennow - President
Beata Garay-Toth - Vice-President
Alexandra Portales - Secretary
Despo Charalambous Demetriou - Treasurer
Counsellors:
Ann Tyrrell Kennedy
Kim Fligelstone
Joep Welling
Linda Schraven
Nadine Paciotti

Local Organising Committee
Marie-Elise Truchetet
Joel Constans
Alain Taieb
Julien Seneschal
Eric Hachulla
Carine Boulon
Géraldine Wojtasik
Sandrine Morell-Dubois

FESCA Local Organising Committee
Dominique Godard - President of the French Scleroderma Association
Yanne Courcoux
Different people. Different symptoms. Same disease.

“\textit{I get heartburn and find it difficult to swallow}”
\textit{Mike}

“I have tight, thick skin and get tired easily”
\textit{Mandy}

“My joints and muscles ache and my fingertips are pale”
\textit{Jessica}

“My hands are puffy and I find it hard to catch my breath”
\textit{Susan}

At Boehringer Ingelheim, we understand how overwhelming a diagnosis of \textbf{systemic sclerosis (scleroderma)} can be for everyone, no matter how the disease manifests itself. Pulmonary involvement is often a particular concern, given that lung complications can be serious and potentially life threatening.\textsuperscript{1}

\textbf{Please visit us at Stand 12 to find out more.}


Date of production: December 2017   PC-CDE-100269

www.morethanscleroderma.com
Roche-sponsored satellite symposium at SSWC 2018

Advancing Treatment Strategies in SSc

Friday 16th February 2018, 15.50–16.20
Auditorium A, Bordeaux Convention Centre

Welcome and introduction
Prof Oliver Distler (Chair)
University Hospital Zurich, Switzerland

Burden of disease and emerging role of IL-6 in SSc
Prof Christopher Denton
Royal Free Hospital and UCL Division of Medicine, London, UK

Perspectives and ongoing clinical trial development in SSc
Prof Dinesh Khanna
University of Michigan, Ann Arbor, USA

Summary
Prof Oliver Distler (Chair)

Question and answer session
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCIENTIFIC PROGRAMME</td>
<td>pag. 6</td>
</tr>
<tr>
<td>WORKSHOP PROGRAMME</td>
<td>pag. 12</td>
</tr>
<tr>
<td>SATELLITE SYMPOSIA</td>
<td>pag. 14</td>
</tr>
<tr>
<td>PATIENT PROGRAMME</td>
<td>pag. 17</td>
</tr>
<tr>
<td>POSTER SESSION</td>
<td>pag. 22</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>pag. 48</td>
</tr>
<tr>
<td>SCIENTIFIC INFORMATION</td>
<td>pag. 49</td>
</tr>
<tr>
<td>CONGRESS FLOORPLANS</td>
<td>pag. 50</td>
</tr>
</tbody>
</table>
THURSDAY, FEBRUARY 15

13:00-16:30
Pre-Congress Workshops
See information at page 12

16:45-17:45
Satellite Symposia
See information at page 14

18:00-18:30
Auditorium A
Opening Ceremony

18:30-19:50
Auditorium A
Opening Lectures
Chairpersons: T Krieg (D), M Matucci-Cerinic (I)

18:30
Clinical progress since last WSC
D Furst (USA)

18:55
Progress in basic science since last WSC
A Gabrielli (I)

19:20
TREATMENT WITH MYELOABLATION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION NORMALIZES THE SSC MOLECULAR SIGNATURE
S Assassi et al (USA)

19:35
DECIPHERING THE GENETIC BACKGROUND OF SSC THROUGH A META-GWAS STRATEGY
E Lopez-Isac et al (E)

19:50
Cheese & Wine Welcome Reception

FRIDAY, FEBRUARY 16

08:00-09:00 Session 1
MEET THE PROFESSOR SESSIONS

Myositis
M Baron (CDN)

GI
V Steen (USA)

Kidney
C Denton (UK)

Auto Ab
T Medsger (USA)

Management Dispnia in SSc
D Tashkin (USA)

Management of early diseases in SSc
M Mayes (USA) & J Seibold (USA)

Echocardiography beyond PAH
L Gargani (I)

Skin issue beyond fibrosis
T Krieg (D)

Lung (PAH)
O Distler (CH)

09:05-10:30 Session 2
Auditorium A
PULMONARY
Chairpersons: R Silver (USA), O Kowal-Bielecka (PL)

09:05
Similarities and differences between IPF and SSc-ILD
B Crestani (F)
FRIDAY, FEBRUARY 16

09:30
SKIN PROGRESSION IS ASSOCIATED WITH INTERNAL ORGAN INVOLVEMENT AND MORTALITY IN PATIENTS WITH DIFFUSE CUTANEOUS SSC: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) ANALYSIS
W Wu et al (CH)

09:45
THORACIC LYMPHADENOPATHY: A CANDIDATE AS A VERY EARLY MARKER OF INTERSTITIAL LUNG DISEASE IN SSC PATIENTS?
C Rotondo et al (I)

10:00
AMBITION STUDY: INITIAL COMBINATION THERAPY OF AMBRISENTAN AND TADALAFIL IN CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (CTD-PAH) IN THE MODIFIED INTENTION TO TREAT POPULATION
M Kuwana et al (JPN)

10:15
LOW LEVELS OF CXCL5 AND CCL5 CORRELATE WITH INCIDENT PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SSC
K Kolstad et al (USA)

10:30-11:00 Coffee Break

11:00-11:55 Session 3 Auditorium A CARDIAC
Chairpersons: A Balbir-Gurman (ISR), G Riemekasten (D)

11:00
How to bring cardiac involvement to light in SSc
M D’Alto (I)

11:25
CLINICAL AND ECHOCARDIOGRAPHIC ASSOCIATES OF ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH SSC
N Boonstra et al (NL)

11:40
CARDIOVASCULAR MAGNETIC RESONANCE PREDICTS RHYTHM DISTURBANCES IN SSC: RESULTS FROM THE SCLERODERMA ARRHYTHMIA CLINICAL UTILITY STUDY [SANCTUS]
L Gargani et al (I)

11:55-12:30 Satellite Symposia
Auditorium C AUTOANTIBODIES
Chairpersons: C Chizzolini (CH), F del Galdo (UK)

12:05-13:40 Satellite Symposia
See information at page 14

13:40-14:40 Poster Session & Lunch

14:40-15:40 Satellite Symposia
See information at page 14

15:50-16:20 Satellite Symposia
See information at page 14

16:25-17:20 Parallel Session 4 Auditorium A AUTOANTIBODIES
Chairpersons: C Chizzolini (CH), F del Galdo (UK)

16:25
New Autoantibodies, organ involvement and disease progression in SSc
M Kuwana (JPN)

16:50
IVIG still the best biologics for SSc?
Y Levy (ISR)

17:05
Should we screen for RNA Pol III?
M Lazzaroni (I)

16:25-17:25 Parallel Session 5 Auditorium C ADVANCED TOOLS (STRATEGIES) FOR DELINEATING FIBROSIS MECHANISMS
Chairpersons: J Varga (USA), Y Asano (JPN)

16:25
Mesenchymal cells in tissue repair, regeneration and fibrosis
C Ventura (I)

16:55
DIPEPTIDYL-PEPTIDASE-4 (DPP4) IDENTIFIES A POPULATION OF FIBROSIS-PROMOTING FIBROBLASTS AND IS A POTENTIAL MOLECULAR TARGET FOR TREATMENT OF FIBROSIS
A Soare et al (D)
FRIDAY, FEBRUARY 16

17:10
MULTI-ORGAN RNA-SEQUENCING OF PATIENTS WITH SSC FINDS THAT INTRINSIC SUBSETS ARE CONSERVED ACROSS ORGAN SYSTEMS
M Whitfield et al (USA)

17:25-17:50 Coffee Break

17:50-18:50 Parallel Session 6 Auditorium C
FIBROSIS IN SSC: CAUSE(S) AND CONSEQUENCES
Chairpersons: R Lafyatis (USA), J Distler (D)

17:50
Lessons from normal wound healing for the pathogenesis of fibrotic diseases
SA Eming (D)

18:20
MYELOID SPECIFIC DELETION OF C-REL PROTECTS AGAINST FIBROSIS IN THE BLEOMYCIN MOUSE MODEL OF SSC
J Worrell et al (UK)

18:35
IL-31 PROMOTES PATHOGENIC MECHANISMS IN SCLERODERMA AND INDUCES SKIN FIBROSIS IN MICE
R Stratton et al (UK)

17:50-18:50
Parallel Session 7 - Round Table Auditorium A
RECENT ACHIEVEMENT AND THE VISION OF REGISTRIES
Chairpersons: S Johnson (CDN), L Czirjak (H)

17:50
EUSTAR registries
Y Allanore (F)

18:02
Canada registries
M Baron (CDN)

18:14
Australia registries
S Proudmann (AUS)
08:00-09:05 Parallel Session 9 Auditorium C
ORAL PRESENTATIONS
Chairpersons: M Nikpour (AUS), D Launay (F), J Wang (RC)

08:00
LOWER-LIMB ULCERS IN SSC: A MULTICENTRIC RETROSPECTIVE CASE-CONTROL STUDY
P Senet et al (F)

08:10
ESSENTIAL ROLE OF THE PROLYL 3-HYDROXYLASE LEPR EL1 IN FIBROSIS
R Stratton et al (UK)

08:20
DEVELOPMENT OF AVID200, AN ISOFORM-SELECTIVE TGF-BETA INHIBITOR, FOR THE TREATMENT OF SSC
M O'Connor et al (CDN)

08:30
DOWN-REGULATION OF MICRORNA-126 IN SCLERODERMA MICROVASCULAR ENDOTHELIAL CELLS IS ASSOCIATED WITH DEFECTIVE ANGIogenesis AND ENHANCE ENDOTHELIAL TO MESENCHYMAL TRANSITION OF (ENDO-MT)
B Kahaleh et al (USA)

08:40
PREDICTION OF FIBROSIS PROGRESSION IN SSC BY COLLAGEN BIOMARKERS
R Dobrota et al (CH)

08:50
CORRELATION BETWEEN CAPILLAROSCOPIC CLASSIFICATIONS, DIGITAL ARTERIAL PRESSURE & DISEASE STAGE IN SSC: BASELINE RESULTS FROM SCLEROCAP STUDY
J Constans et al (F), S Blaise et al (F)

09:10-10:10 Session 10 Auditorium A
FREQUENTLY ASKED QUESTIONS
Chairpersons: T Frech (USA), E Kucharz (PL)

09:10
Should we repeat NVC in the follow up of SSC?
J Constans (F)
SATURDAY, FEBRUARY 17

09:25
Should we repeat HRCT during the follow up of SSc?
D Tashkin (USA)

09:40
What is patient education and how to deliver it?
S Jacquemet (CH)

09:55
When do we need to make macro/micro vascular assessment when you see a DU?
M Matucci-Cerinic (I)

10:10-10:40 Coffee Break

10:40-12:05 Session 11 Auditorium A
MISCELLANEOUS
Chairpersons: M Hinchcliff (USA), S Guiducci (I)

10:40
The microbiota in SSc
A Hoffmann-Voldt (N)

11:05
THE INTESTINAL INVOLVEMENT IN SSC IS CHARACTERIZED BY A PECULIAR GUT MICROBIOTA: CORRELATION WITH DISEASE SUBTYPES AND BMI
G Natalello et al (I)

11:20
THE PREDICTOR OF MALNUTRITION IN SYSTEMIC SCLEROSIS SCORE; PREMASS: THE FIRST VALIDATED COMBINED INDEX PREDICTIVE OF FUTURE WEIGHT LOSS IN SSC
G Bagnato et al (I)

11:35
Oral Maxillary involvement in SSc
ME Truchetet (F) & R Devillard (F)

11:50
SCLERORAL STUDY: CLINICAL AND RADIOLOGICAL ANALYSIS OF ORAL MANIFESTATIONS ASSOCIATED TO SSC
S Jung et al (KR)

12:15-13:15
Satellite Symposia
See information at page 14

13:15-14:20
Poster Session & Lunch

14:20-14:50
Satellite Symposia
See information at page 14

14:50-16:45 Session 12 Auditorium A
TREATMENT
Chairpersons: M Mayes (USA), A Herrick (UK)

14:50
DU lessons and perspectives from RCT
E Hachulla (F)

15:15
How to manage limited SSc
Y Allanore (F)

15:40
SSc-ILD: when to treat and for how long?
D Khanna (USA)

16:05
WORLDWIDE EXPERT AGREEMENT ON 2016 EULAR/EUSTAR RECOMMENDATIONS FOR THE TREATMENT OF SSC
J De Vries-Bouwstra et al (CH)

16:15
LONGITUDINAL CLINICAL, MOLECULAR, AND IMMUNOHISTOCHEMISTRY CHANGES DURING MYCOPHENOLEATE MOFETIL THERAPY IN PATIENTS WITH SSC
D Toledo et al (USA)
SATURDAY, FEBRUARY 17

16:25
Efficacy of adipose tissue-derived cell regional implantation in the treatment of cardinal digital ulcers in patients with SSC. Results of a randomised controlled trial
N Del Papa et al (I)

16:35
Rituximab in SSC: safety and efficacy data from the EUSTAR network
M Elhai et al (F)

16:45-17:25 Auditorium A
Highlights of the Congress
Chairpersons: K Takehara (JPN), L Mouton (F)
Speakers: O Distler (CH) & S Assassi (USA)

17:25-17:40 Auditorium A
Closure of the Congress
WORKSHOP PROGRAMME

NEW INSIGHTS ON THE APPLICATIONS OF ULTRASOUND IN UNDERSTANDING AND MANAGING SSC

Convenor: E Naredo (E)

13.00 and 15:00
Welcome
Clinical case
E Naredo (E)

13.05 and 15:05
Anatomic basis and ultrasound imaging of synovium and tendon involvement in SSC
I Möller (E)

13.15 and 15:15
Workshop on joints and tendons in SSC
I Möller (E), M Micu (RO), D Botello (E), E Naredo (E)

WORKSHOP PROGRAMME

Workshops will be held on Thursday, February 15, for registered participants only.

Reservation is requested.
Left places can be booked at the “New Registration” desk in the registration area.

Coordinator: Phil Clements (USA)

Workshops will be repeated twice in the following times:
From 13:00 to 14:30 first slot
From 15:00 to 16:30 second slot

A coffee break will be served in the foyer from 14:30 to 15:00

HOW TO USE NAILFOLD CAPILLAROSCOPY IN SSC

Convenor: M Cutolo (I)

13:00 and 15:00
Why capillaroscopy in SSC is fundamental for clinical/basic research and for the early diagnosis
M Cutolo (I)

13:15 and 15:15
How to distinguish the pathological capillaroscopic patterns from a normal pattern and role in prediction of clinical complications in SSC
V Smith (B)

13:30 and 15:30
How to select and when to emply the capillaroscopic device
A Sulli (I)

13:40 and 15:40
Practical session with patients

LOCALIZED SCLERODERMA

Convenors: R Knobler (A), T Krieg (D), A Taieb (F), K Takehara (J)

13:00 and 15:00
Introduction
T Krieg (D)

13:05 and 15:05
Classification of localized scleroderma
P Moinzadeh (D)

13:20 and 15:20
The Japanese network - an update
T Makino (J)

13:30 and 15:30
The natural course of localized scleroderma
J Mertens (NL)

13:40 and 15:40
Discussion

13:50 and 15:50
Topical and systemic therapy
A Taieb (F)
THURSDAY, FEBRUARY 15

14:05 and 16:05
UV-Therapy
R Knobler (A)

14:15 and 16:15
Discussion

14:25 and 16:25
Conclusion
K Takehara (J)

HOW TO EXPLORE THE VASCULAR SYSTEM
Convenor: J Constans (F)

13:00 and 15:00
Introduction
P Carpentier (F), J Constans (F)

13:05 and 15:05
Interactive clinical cases
Clinical case I: How to predict a digit ulcer?
S Blaise (F), C Boulon (F)

Clinical case II: Vascular exploration of a sclerodermic patient with digit ulcer
I Lazareth (F)

Clinical case III: lower limb ulcer in a sclerodermic patient
P Senet (F)

14:05 and 16:05
Manipulation of devices
Wide field capillaroscopy
Laser Doppler
Digital pressure measurement
Transcutaneous oxygen pressure measurement

The workshop is supported by the Societe Francaise de Medecine Vasculaire and Societe Francaise de Microcirculation

DIGITAL ULCER MANAGEMENT
Convenor: M Matucci-Cerinic (I)

13:00 and 15:00
The classification and the therapeutic strategy of DU in SSc
M Matucci-Cerinic (I)

13:25 and 15:25
The assessment of the ulcer (characteristics of the wound, infections, gangrene) in SSc
D Giuggioli (I)

13:50 and 15:50
The topical treatment of digital ulcerations with video projected procedures
C Bruni (I)

Video will be shown and the following points will be discussed in interactive fashion:
• what to look at
• how to wash/clean
• which kind of anesthesia
• how to perform debridement
• how to choose the dressing and covering.

SKIN BIOPSY- A PRACTICAL WORKSHOP
Convenors: A Ramming (D), R Dobrota (CH)

SKIN SCORING – A PRACTICAL WORKSHOP
Convenors: L Czirjak (H), D Furst (USA)

DETERMINING PROGRESSION OF SSC-ILD
Convenor: D Tashkin (USA), E Volkmann (USA)

Important!
The following workshop will be held from 15:00 to 16:30 only at the Hotel Pullman - Room Montaigne A

SKIN SCORE IN JUVENILE SSC
Convenors: D Khanna (USA), I Foeldvari (D)
The workshop is supported by Bayer AG
CORBUS PHARMACEUTICALS, INC.
SATELLITE SYMPOSIUM

AUDITORIUM A

Thursday, February 15
16:45-17:45

TARGETING INNATE IMMUNITY IN SCLERODERMA
Chairperson: J Varga (USA)

16:45
Innate Immune Responses and Fibrosis in Scleroderma
J Varga (USA)

17:15
Resolving Innate Immune Responses in Scleroderma
B White (USA)

ACTELION
SATELLITE SYMPOSIUM

AUDITORIUM A

Friday, February 16
12:05-13:40

TIMELY AND EFFECTIVE DECISIONS IN PAH-SSC
Chairpersons: Y Allanore (F), M Matucci-Cerinic (I)

12:05
Introduction
Y Allanore (F)

12:10
Identification and treatment of PAH-SSc patients at an early disease stage
D Khanna (USA)

12:30
Utilization of risk assessment for the management of patients
A Boucly (F)

12:50
Double oral combination - The way forward for all PAH-SSc patients?
D Dumitrescu (D)

13:10
The role of the prostacyclin pathway in the treatment of PAH-SSc
K Highland (USA)

13:30
Panel discussion
M Matucci-Cerinic (I)
BOEHRINGER INGELHEIM
SATELLITE SYMPOSIUM

Friday, February 16
14:40-15:40

PULMONARY INVOLVEMENT IN SSC - ARE WE ADDRESSING THE BURDEN?
Chairperson: Y Allanore (F)

14:40
Burden of interstitial lung disease associated with SSc
Y Allanore (F)

14:50
Current evidence on treatment of interstitial lung disease associated with SSc
E Volkmann (USA)

15:00
How can we better select patients with interstitial lung disease associated with SSc for treatment?
O Distler (CH)

15:10
Innovative therapeutic approaches to interstitial lung disease associated with SSc
B Crestani (F)

15:20
Questions and answers

ROCHE
SATELLITE SYMPOSIUM

Friday, February 16
15:50-16:20

ADVANCING TREATMENT STRATEGIES IN SSC
Chairperson: O Distler (CH)

Welcome and introduction
O Distler (CH)

Burden of disease and emerging role of IL-6 in SSc
C Denton (UK)

Perspectives and ongoing clinical trial development in SSc
D Khanna (USA)

Summary
O Distler (CH)

Question and answer session
MSD/BAYER SATELLITE SYMPOSIUM

Saturday, February 17
12:15-13:15

2018 UPDATE ON PULMONARY ARTERIAL HYPERTENSION – CONNECTIVE TISSUE DISEASE
Chairperson: D Khanna (USA)

12:15 Welcome and Opening Remarks
D Khanna (USA)

12:20 What’s new in SSc?

EUSTAR Predictors of dcSSc
O Distler (CH)

Current EULAR Recommendations
M Matucci-Cerinic (I)

12:45 Screening for and Diagnosing PAH in SSc Patients
H A Ghofrani (D)

12:55 sGC Stimulation in PAH-CTD Patients: Results From the Pivotal PATENT Study
M Humbert (F)

13:05 Round Table Q&A
D Khanna (USA)

13:15 Summary and Close
D Khanna (USA)

ITALFARMACO SATELLITE SYMPOSIUM

Saturday, February 17
14:20-14:50

SSC-RELATED VASCULAR DISEASE: STATE OF THE ART AND FUTURE PERSPECTIVES OF PROSTANOID THERAPY
Chairperson: DE Furst (USA)

14:20 The burden of SSc vascular disease
DE Furst (USA)

14:35 The role of iloprost in the treatment of RP and DUs
F Iannone (I)
### THURSDAY, FEBRUARY 15

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td><strong>ROUND-TABLE NETWORKING MEETING FOR LEADERS OF PATIENT ASSOCIATIONS</strong>&lt;br&gt;Theme: How to deal with psychological aspect of newly diagnosed patients?&lt;br&gt;Facilitator: Brett D. Thombs (CAN), Ph.D. Professor, Faculty of Medicine, McGill University&lt;br&gt;20 min to present SPIN + opened discussions</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>OPENING LECTURES AND WELCOME RECEPTION FOR CLINICIANS AND PATIENTS</strong></td>
</tr>
</tbody>
</table>

Simultaneous translation in French and Spanish is provided in **Auditorium B** on **Friday, February 16** and **Saturday, February 17**.
# Friday, February 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium B</th>
<th>Room F1</th>
<th>Room E2</th>
<th>Room E1</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>FESCA Welcome&lt;br&gt;by President Annelise ROENNOW (DK)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:05</td>
<td>HAVE WE LEARNT NEW THINGS ABOUT SCLERODERMA?&lt;br&gt;Speaker: Prof. Yannick ALLANORE (F)&lt;br&gt;20 min + 5 min Q&amp;A&lt;br&gt;Chair: Annelise ROENNOW (DK) and Prof. Dan FURST (USA)</td>
<td>9:30-12:00&lt;br&gt;Focus group: barriers and facilitators to physical activity in scleroderma (ENGLISH and FRENCH)&lt;br&gt;Dr. Brett THOMBS (CAN), Julie Cumin (CAN), Marie-Eve Carrier (CAN)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>WHEN FIBROSIS STRIKES THE HEART OR LUNGS IN SSc&lt;br&gt;Speaker: Dr. Roger HESSELSTRAND (S)&lt;br&gt;20 min + 10 min Q&amp;A&lt;br&gt;Chair: Monica HOLMNER (S) and DR Anne Braae OLESEN (DK)</td>
<td>9:30-12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>MOUTHCARE AND DENTAL TREATMENTS FOR PATIENT WITH SEVERE SSc&lt;br&gt;Speaker: Dr. Sophie JUNG (F) - 20 min&lt;br&gt;Patient experience: Anna VEGH (H) - 10 min&lt;br&gt;Chair: Stephan HOUBERTZ (D) and Dr. Voon ONG (UK) Q&amp;A - 10 min</td>
<td>10:00-11:00&lt;br&gt;Posture and breathing exercises for SSc&lt;br&gt;Jadranka BROZD, Sanja ROSKAR (HR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10</td>
<td>PLASTIC SURGERY: FACE/LIPS, SOLE, ETC. ANY DEVELOPMENT?&lt;br&gt;Speaker: Dr. Louise PASQUESOONE (F)&lt;br&gt;20 min + 10 min Q&amp;A&lt;br&gt;Chair: Nadine PACIOTTI (CH) and Prof. Marco MATUCCI-CERINIC (I)</td>
<td>11:00-11:50&lt;br&gt;Chi Gong&lt;br&gt;Managed by Gabi NIEHAUS (D)</td>
<td>11:00-12:00&lt;br&gt;Wax Bath&lt;br&gt;by Will GREGORY (UK)</td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY, FEBRUARY 16

<table>
<thead>
<tr>
<th>TIME</th>
<th>ROOM</th>
<th>EVENT</th>
<th>SPEAKER(S)</th>
<th>DURATION</th>
<th>CHAIR(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40</td>
<td></td>
<td>SURGERY: SPECIFIC RECOMMENDATIONS FOR SSc PATIENTS</td>
<td>Prof. Luc MOUTHON (F) - 15 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>How to prevent and treat digital ulcers</td>
<td>Michele TONDUT (F) + Dr. S. SKOPINSKI (F)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Juvenile Scleroderma</td>
<td>Dr. Ivan FOELDVARI (D)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Patient experience:</td>
<td>Yun WAH (UK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td></td>
<td>URINARY PROBLEMS</td>
<td>Dr. Gregor JOHN (CH)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td></td>
<td></td>
<td>Dr. Ivan FOELDVARI (D)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td>Yann WAIK (UK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td>EDUCATIONAL THERAPY</td>
<td>Dr. Silvia BREDA (I)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td>HOW TO HANDLE UPPER/LOWER INTESTINAL TRACT PROBLEMS?</td>
<td>Prof. Dinesh KHANNA (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td>The Benefits of Sophrology in SSc</td>
<td>Dr. Natalia CAYCEDO (E)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td>Dr. Brett THOMBS (CAN)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td>Educational Therapy in French</td>
<td>Dr. Sandrine MORELL-DUBOIS (F)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td>Educational Therapy in English</td>
<td>Dr. Sandrine MORELL-DUBOIS (F)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td>Educational Therapy in English</td>
<td>Dr. Sandrine MORELL-DUBOIS (F)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Simultaneous translation in French and Spanish is provided in Auditorium B only
### PATIENT PROGRAMME

**SATURDAY, FEBRUARY 17**

Simultaneous translation in French and Spanish is provided in Auditorium B only.

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium B</th>
<th>Room F1</th>
<th>Room E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-10:00</td>
<td><strong>MEET THE PROFESSOR</strong>&lt;br&gt;Answers to your questions in&lt;br&gt;<strong>ENGLISH</strong>&lt;br&gt;Prof Dan FURST (USA),&lt;br&gt;Prof. Maureen MAYES (USA),&lt;br&gt;Dr. Pia MOINZAHEH (D)</td>
<td><strong>MEET THE PROFESSOR</strong>&lt;br&gt;Answers to your questions in&lt;br&gt;<strong>FRENCH</strong>&lt;br&gt;Prof. Yannick ALLANORE (F),&lt;br&gt;Prof. Eric HACHULLA (F)</td>
<td><strong>MEET THE PROFESSOR</strong>&lt;br&gt;Answers to your questions in&lt;br&gt;<strong>GERMAN</strong>&lt;br&gt;Prof. Dr. Miklós SÂRDY (H)</td>
</tr>
<tr>
<td>10:00-10:45</td>
<td><strong>DEVELOPMENT OF NEW THERAPIES IN SSc</strong>&lt;br&gt;• How to identify new therapies in the laboratory&lt;br&gt;Prof. Dr. Jörg DISTLER (D) - 15 min&lt;br&gt;• New therapies for SSc: Update on ongoing clinical studies&lt;br&gt;Prof. Dr. Oliver DISTLER (CH) - 20 min&lt;br&gt;Chair: Joep WELLING (NL)&lt;br&gt;Q&amp;A - 10 min</td>
<td><strong>10:00-11:00</strong>&lt;br&gt;<strong>SOPHROLOGY IN SPANISH</strong>&lt;br&gt;Managed by <strong>Martine TORRENT (F)</strong></td>
<td><strong>10:00 am-01:00 pm</strong>&lt;br&gt;Focus group: barriers and facilitators to physical activity in scleroderma (ENGLISH and FRENCH)&lt;br&gt;Dr. Brett THOMBS (CAN), Julie Cumin (CAN), Marie-Eve Carrier (CAN)</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td><strong>TREATING PAIN IN DIGITAL ULCERS &amp; CALCINOSIS</strong>&lt;br&gt;Speaker:&lt;br&gt;Prof. Anne-Laure FAUCHAIS (F)&lt;br&gt;20 min + 10 min Q&amp;A&lt;br&gt;Chair: <strong>Kim FLIGELSTONE (UK)</strong> and <strong>Prof. Eric HACHULLA (F)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15-11:45</td>
<td><strong>RESEARCH ON KIDNEY FAILURE IN SSc</strong>&lt;br&gt;Speaker: <strong>Prof. Chris DENTON (UK)</strong>&lt;br&gt;20 min + 10 min Q&amp;A&lt;br&gt;Chair: <strong>Despo CHARALAMBOUS (CY)</strong> and <strong>Dr. Carina MIHAI (RO)</strong></td>
<td></td>
<td><strong>11:45-12:45</strong>&lt;br&gt;<strong>SOPHROLOGY IN FRENCH</strong>&lt;br&gt;Managed by <strong>Martine TORRENT (F)</strong></td>
</tr>
<tr>
<td>12:15-12:45</td>
<td><strong>NUTRITION IN SSc</strong>&lt;br&gt;Speaker: <strong>Dr. Lesley Ann SAKETKOO (USA)</strong>&lt;br&gt;20 min + 10 min Q&amp;A&lt;br&gt;Chair: <strong>Gabi NIEHAUS (D)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COFFEE BREAK**
## SATURDAY, FEBRUARY 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium B</th>
<th>Room F1</th>
<th>Room E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td><strong>Self Management: Overcoming Obstacles in Education and Work</strong>&lt;br&gt;Speaker: Yun WAH (UK)&lt;br&gt;Chair: Annelise ROENNOW (DK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:55</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Closing</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
POSTER SESSION

Poster session will take place in the Poster Area on Friday, February 16 from 13:40 to 14:40 and on Saturday, February 17 from 13:15 to 14:20.

Posters have been given a number and must be fixed on the poster board marked with the same number.

Posters can be hanged from 15:00 to 18:00 on Thursday, February 15 and from 07:45 on Friday, February 16 and removed within 18:00 on Saturday, February 17.

Poster panel height is cm 215 and the usable surface in vertical size is cm. 90 (width) and cm. 160 (height).

Authors are kindly asked on Friday, February 17 and Saturday, February 18 to stand by their poster during the Poster Session time for discussion with delegates. Otherwise please hang a note to inform when you will be available.

PATHOGENESIS

P.001 A NOVEL ANIMAL MODEL FOR SYSTEMIC SCLEROSIS INDUCED BY IMMUNIZATION OF ANGIOTENSIN II RECEPTOR 1
X. Yue, G. Riemekasten, X. Wang, H. Heidecke, F. Petersen, X. Yu

P.002 SKIN COMMENSAL BACTERIA MIGHT AFFECT WOUND REPAIR IN SSC BY PREVENTING FIBROBLAST ACTIVATION AND BY PROVOKING CHRONIC INFLAMMATORY REACTIONS
M. Yokota, J. Schniering, O. Distler, B. Maurer

P.003 THE AV INTEGRIN INHIBITOR ABITUZUMAB HIBITIS MYOFIBROBLAST DIFFERENTIATION
E. Samy, Y. Wu, G. Higginbotham, R. Grenningloh, D. Xu

P.004 C-REL IS A MASTER REGULATOR OF FIBROBLAST PHENOTYPE AND CELLULAR INTERACTIONS IN PULMONARY AND DERMAL FIBROSIS
J. Worrell, J. Leslie, G. Smith, S. O'Reilly, M. Zaki, J. Van Laar, D. Mann, F. Oakley

P.005 GENERATION AND CHARACTERIZATION OF ANTIBODIES AGAINST AT1R IN MOUSE MODEL OF SYSTEMIC SCLEROSIS (SSC)

P.006 EXPRESSION OF TLR7, TLR9, JAK2 AND STAT3 GENES IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS
M. Vreca, V. Spasovski, A. Zekovic, N. Damnjanov, M. Andjelkovic, M. Ugrin, S Pavlovic

P.007 VITAMIN D IN SYSTEMIC SCLEROSIS PATIENTS WITH DRY EYE SYNDROME
E. Visalli, C. Gagliano, M. Di Gangi, G. Amato, A. Benenati, T. Avitabile, R. Foti

P.008 REACTIVITY OF 150-KD ALPHA 2(V) CHAIN OF TYPE V COLLAGEN IS ASSOCIATED WITH AUTOIMMUNITY IN EARLY SYSTEMIC SCLEROSIS

P.009 COLLAGEN V/C57BL6 MOUSE MODEL: A NOVEL PRECLINICAL MODEL TO STUDY PATHOPHYSIOLOGY AND THERAPEUTIC APPROACHES IN SYSTEMIC SCLEROSIS

P.010 SERUM KLOTHO CONCENTRATION IS INVERSELY ASSOCIATED TO THE SEVERITY OF NAILFOLD CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS PATIENTS
R. Talotta, T. Letizia, S. Bongiovanni, F. Rigamonti, M.C. Ditto, M. Antivalle, V. Varisco, S. Santandrea, F. Atzeni, T. Vago, P.C. Sarzi-Puttini

P.011 INCREASED PLASMA LEVELS OF HSP90 ARE ASSOCIATED WITH LUNG INVOLVEMENT AND SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.012 METABOLITES OF COLLAGEN ARE ASSOCIATED WITH THE AMOUNT OF FIBROSIS IN INTERNAL ORGANS IN SYSTEMIC SCLEROSIS PATIENTS
P.013 ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND OTHER SYSTEMIC AUTO-IMMUNE DISEASES: STUDY IN TWO UNIVERSITY HOSPITALS COHORTS
M. Scherlinger, J. Lute, E. Chatelus, M.E. Truchetet

P.014 CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN-4 EXPRESSION INCREASED IN LESIONAL LINEAR MORPHEA FIBROBLASTS
M. Nino Leon, X. Shi Wen, C. Fonseca, C. Orteu, D. Abraham, C. Denton, A. Saracino, M. Ponticos

P.015 DISEASE-RELATED SITE SPECIFIC METABOLIC REPROGRAMMING IN LINEAR MORPHEA FIBROBLASTS

P.016 THE FIRST COMPREHENSIVE ANALYSIS OF ANTIGEN-SPECIFIC CYTOMEGALOVIRUS ANTIBODY RESPONSES IN PATIENTS WITH SSC

P.017 INCREASED PHOSPHORYLATION OF SYK KINASE IN B CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS
L. Sakkas, A. Mavropoulos, T. Simopoulou, C. Liaskos, D. Bogdanos

P.018 EPITOPE MAPPING OF ANTI-RO52 ANTIBODY RESPONSES REVEALS DISTINCT IMMUNODOMINANT EPITOPE RECOGNITION IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO SYSTEMIC LUPUS ERYTHEMATOSUS

P.019 WITHDRAWN

P.020 WITHDRAWN

P.021 DYSREGULATION OF THE SLIT/ROBO AXIS MAY CONTRIBUTE TO ANGIOGENESIS DISTURBANCE IN SYSTEMIC SCLEROSIS (SSC)
E. Romano, M. Manetti, I. Rosa, B.S. Fioretto, L. Ibba-Manneschi, M. Matucci-Cerinic, S. Guiducci

P.022 SINGLE CELL CLONING FROM HEALTHY AND SCLERODERMA SKIN BIOPSIES REVEALS SPECIFIC SUBSETS OF DERMAL FIBROBLASTS WITH DIFFERENTIAL PROFIBROTIC RESPONSES
R. Rebecca, C. Corinaldesi, N. Riobo-Del Galdo, F. Del Galdo

P.023 SYSTEMIC SCLEROSIS AND CANCER DEVELOPMENT. A SINGLE-CENTRE EXPERIENCE
E. Kaltsonoudis, E. Pelechas, P. Voulgari, A. Drosos

P.024 IMPACT OF ALTERATIONS IN X-LINKED IRAK1 GENE AND MIRNA-146A ON SUSCEPTIBILITY AND CLINICAL MANIFESTATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS
S. Pavlovic, M. Vreca, M. Andjelkovic, A. Zekovic, N. Damjanov, V. Spasovski

P.025 CHEMERIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS CORRELATE WITH VASCULAR DAMAGE

P.026 EVALUATION OF HLA-G IN SYSTEMIC SCLEROSIS
G. Murdaca, P. Contini, S. Negrini, M. Borro, F. Pupo

P.027 THE CONTRIBUTION OF DYSFUNCTIONAL ENDOTHELIAL CELLS TO THE VASCULOPATHY OF SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW

P.028 CCL18 AS BIOMARKER OF DISEASE ACTIVITY IN LOCALIZED SCLERODERMA AND EOSINOPHILIC FASCIITIS

P.029 SYSTEMIC SCLEROSIS SERA IMPAIR DERMAL LYMPHATIC MICROVASCULAR ENDOTHELIAL CELL FUNCTIONALITY
M. Manetti, E. Romano, I. Rosa, B.S. Fioretto, S. Guiducci, L. Ibba-Manneschi, M. Matucci-Cerinic

P.030 SERUM EOTAXIN-1/CCL11 LEVELS ARE ELEVATED IN SYSTEMIC SCLEROSIS AND ARE ASSOCIATED WITH SEVERITY

P.031 CIRCULATING MONOCYTE SUB-POPULATIONS ACCORDING TO CD14 AND CD16 EXPRESSION IN SYSTEMIC SCLEROSIS
A. Lescoat, A. Ballerie, M. Roussel, B. Ly Sunnaram, G. Coiffier, S. Jouveau, O. Fardel, T. Fest, P. Jégo, V. Le Cureur
PATHOGENESIS

P.032 DISTINCT PROPERTIES OF M- AND GM-BLOOD MONOCYTE-DERIVED MACROPHAGES TO SIMULATE PATHOLOGICAL LUNG CONDITIONS IN VITRO: APPLICATION TO SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
A. Ballerie, A. Lescoat, Y. Augagneur, L. Vernhet, O. Fardel, P. Jégo, S. Jouneau, V. Lecureur

P.033 EFFEROCYTOSIS ABILITY OF MONOCYTE-DERIVED MACROPHAGES IN SYSTEMIC SCLEROSIS: FUNCTIONAL AND PHENOTYPIC EVALUATION
A. Ballerie, A. Lescoat, C. Cazalets, S. Jouneau, L. Vernhet, O. Fardel, P. Jégo, V. Lecureur

P.034 MALIGNANCIES IN PATIENTS WITH CONNECTIVE TISSUE DISEASES AND POSITIVITY FOR ANTI-PM/SCL. A SINGLE CENTER STUDY
M.G. Lazzaroni, I. Cavazzana, N. Carabellese, A. Montanelli, A. Furloni, A. Tincani, F. Franceschini, P. Airò

P.035 A NOVEL COMPUTATIONAL APPROACH TO IDENTIFY NEW Targets AND PATHWAYS FOR THERAPEUTIC INTERVENTION IN SCLERODERMA
E. Kurtagic, J. Pradines, T. Manning, I. Capila

P.036 INCREASED EXPRESSION OF THE TNF SUPERFAMILY MEMBER LIGHT/TNFSF14 AND ITS RECEPTORS (HVEM AND LTBR) IN THE SKIN OF PATIENTS WITH SYSTEMIC SCLEROSIS
O. Kowal-Bielecka, E. Gindzienska-Sieskiewicz, J. Reszec, P. Bielecki, A. Sieskiewicz, M. Bielecki, A. Sulik, K. Kowal

P.037 METABOLOMIC ANALYSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.038 CHARACTERIZATION OF COLLAGEN FORMATION BY GROWTH FACTORS IN DERMAL FIBROBLASTS
P. Juhl, M.A. Karsdal, A. Bay-Jensen, A.S. Siebuhr

P.039 A LONGITUDINAL ANALYSIS OF IL-7 LEVELS IN SYSTEMIC SCLEROSIS SUGGESTS INCREASED LEVELS IN CASES WITH SCLERODERMA RENAL CRISIS
L. Host, S.I. Nihyanyova, B. Ahmed Abdi, V. Ong, C.P. Denton

P.040 IS CCN3 (NOV) DYSREGULATION IN SSC SKIN THE MISSING LINK BETWEEN VASCULOPATHY AND PIGMENTARY DISORDERS?

P.041 GENOME-WIDE ASSOCIATION ANALYSIS OF SYSTEMIC SCLEROSIS IN IRANIAN POPULATION
D. Gonzalez-Serna, E. Lopez-Isac, M. Brown, F. Gharibdoost, H. Kavosi, S. Poursani, A. Jamshidi, M. Mahmoudi, J. Martin

P.042 GENOME-WIDE ASSOCIATION ANALYSIS OF SYSTEMIC SCLEROSIS IN TURKISH POPULATION

P.043 SOLUBLE CD163 AS A POSSIBLE BIOMARKER IN SYSTEMIC SCLEROSIS
C. Frantz, S. Pezet, Y. Allanore

P.044 FREE THIOL RESPONSE IN HYPOTHERMIA INDUCED RAYNAUD'S ATTACK: A MARKER OF OXIDATIVE STRESS

P.045 PRELIMINARY REPORT OF AUTO-ANTIBODY PROFILES OF SYSTEMIC SCLEROSIS IN ASIAN PATIENTS; SYSTEMATIC REVIEW
A. Ehsani, M. Salesi, H. Poormoghim

P.046 THE ROLE OF IL-17A IN THE INTERPLAY BETWEEN KERATINOCYTES AND FIBROBLASTS IN HUMAN SKIN WITHIN SYSTEMIC SCLEROSIS
A.M. Dufour, M. Alvarez, M.E. Truchetet, N.C. Brembilla, C. Chizzolini

P.047 RNAI-BASED IDENTIFICATION OF NOVEL DRUG TARGETS TO REDUCE ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDOMT) IN HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELLS: A TARGET DISCOVERY APPROACH FOR SCLERODERMA

P.048 WNT5A PROMOTES TISSUE FIBROSIS BY JNK-DEPENDENT ACTIVATION OF LATENT TGF-BETA
C. Chen, T. Trinh-Minh, X. Xu, A. Soare, F. Groeber, A. Schambony, J. Distler

P.049 ACTIVATED STAT3 INTEGRATES IMPORTANT PROFIBROTIC PATHWAYS IN SYSTEMIC SCLEROSIS
PATHOGENESIS

P.050 Biased Initial Phosphorylation of Bruton's Tyrosine Kinase and Phospholipase C Gamma 2 Following B Cell Receptor Activation in Patients with Interstitial Lung Disease Associated to Systemic Sclerosis

P.051 Proteomic Analysis of Human Fibroblasts in Systemic Sclerosis Reinforces the Role of TGF-SS and Points Toward EGFR / PI3K Pathways Inhibition

P.052 Serum Tryptophan (TRP) and Kynurenine (KYn) Levels Are Altered in SSC and Show Distinct Clinical and Autoantibody Associations Suggesting Potential Role in Pathogenesis
C. Campochiaro, S.D. Lytton, S. Nihtyanova, D. Fuchs, V.H. Ong, C.P. Denton

P.053 Clinical Characteristics of Systemic Sclerosis Without Specific Antibodies

P.054 Systemic Lupus Erithematosus with Positive Anticentromere Antibodies - A Different Clinical Subgroup?
J. Caetano, C. Favas, M. Amaral, S. Oliveira, J.D. Alves

P.055 Autoimmunity in Scleroderma: A Comparative Study of 8 Autoantibodies in Patients with Systemic Sclerosis, Systemic Lupus Erithematosus and Healthy Controls
A. Burlui, A. Cardoneanu, E. Rezus

P.056 Prevalence and Clinical Signification of Anti-BICD2 Autoantibodies in a French Cohort of Systemic Sclerosis Patients

P.057 DOT1L Inhibition Reduces the Pro-Fibrotic Effects of TGFβ in Primary Human Dermal Fibroblasts and Increases Fibroblast Viability
N. Berghen, E. De Langhe, R. Lories

P.058 Collagen V Stimulates TGF-beta and Endothelin-1 Expression in Human Fibroblasts and Endothelial Cells
I. Begalli Mendes, S. Carrasco, A.P. Dos Santos Moreira, A.P. Velosa, C. Goldenstein-Schainberg, D. Frediane, W. Teodoro

P.059 Les Caractéristiques Épidémiologiques, Clinico-Biologiques et Évolutives du Scléroderme: A Propos de 16 Cas
I. Rachdi, W. Bani, Z. Aydi, F. Daoud, H. Zoubeidi, B. Ben Dhaou, F. Boussesma

P.060 Autoimmune Diseases in Systemic Sclerosis Patients and Their Relatives; A Single Center Data
A. Balbir-Gurman, V. Shataylo, Y. Braun-Moscovici

P.061 Assessment of In Vitro Responses of Gamma/Deltat Cells from Patients with Systemic Sclerosis to Stimulation with Cardiolipin and Zoledrinate
A. Balbir-Gurman, I. Bank, P. Fisch, J. Villacorta Hidalgo, Y. Braun-Moscovici, H. Migalovich Sheikhet

P.062 CXCL10 Level as Potential Early Serum Biomarker in Systemic Sclerosis
C. Antinozzi, C. Corinaldesi, M. Vasile, V. Riccieri, G. Valesini, F. Ramampon, F. Del Galdo, V. Raparelli, A. Lenzi, C. Crescioli

P.063 Clinical Associations of Vascular Endothelial Growth Factor in Systemic Sclerosis
R. Alekperov, E. Alexandrova, A. Novikov, L. Ananyeva

P.064 The Effect of Ethanol Extract Physalis Angulata on Skin Fibrosis, Inflammatory Process, Biomarker Immunology and Fibrosis Serum in Scleroderma Patients (a Double Blind Randomized Controlled Trial)
S. Dewi, E.H. Purwaningsih, N. Kertia, R. Setiabudy, S. Setiati, H. Isbagio

P.065 Innate Lymphoid Cells Type 2: A New Key Actor in the Pathogenesis of SSC?
C. Peronino, M. Jeljeli, L. Riccio, N. Kavian, F. Batteux

P.066 Role of Trained Macrophages in Fibrosis in an Experimental Model of Systemic Sclerosis
C. Peronino, M. Jeljeli, L. Riccio, N. Kavian, F. Batteux
PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION

P.067 MYCOPHENOLATE MOFETIL AS FIRST LINE TREATMENT IMPROVES EARLY LUNG DISEASE IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS
N. Zotos, M. Gianniki, M. Gerasimou, E. Tatsina, D. Bougias, P. Christodoulou, C. Mitsis, A. Zotou, A. Pournou, N. Tsifetaki

P.068 INTERSTITIAL LUNG DISEASE IN SCL70-POSITIVE SCLERODERMA PATIENTS WITH LIMITED CUTANEOUS FORM
E. Zanatta, P. Polito, E. Balestro, M. Favaro, E. Pigatto, F. Ometto, A. Martini, L. Punzi, F. Cozzi

P.069 A PHASE II RANDOMIZED CONTROLLED TRIAL OF ABITUZUMAB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
D. Khanna, D. Tashkin, A. Wells, J. Goldin, M.W. Lubell, S. Wax, D. Damian, C. Denton

P.070 CHARACTERISTICS OF ANTI-U1RNP-ANTIBODY-POSITIVE PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ARE INFLUENCED BY THE PRESENCE OR ABSENCE OF SYSTEMIC SCLEROSIS FEATURES
H. Yasuoka, H. Takei, Y. Shirai, K. Yamaoka, M. Kuwana, T. Takeuchi

P.071 IMPACT OF LEFT HEART DISEASE-ASSOCIATED PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS IN COMPARISON WITH THOSE WITH NON-SYSTEMIC SCLEROSIS

P.072 PREDICTION OF PROGRESSION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
W. Wu, S. Jordan, M.O. Becker, R. Dobrota, S. Ye, B. Maurer, Y. Allanore, O. Distler

P.073 BARDOXOLONONE METHYL INHIBITS MARKERS OF ENDOTHELIAL-TO-MESENCHYMAL TRANSITION AND FIBROSIS IN HUMAN PULMONARY ARTERY ENDOTHELIAL CELLS
C. Wigley, G. Miller, D. Ferguson

P.074 SALVIANOLIC ACID B ATTENUATES EXPERIMENTAL PULMONARY INFLAMMATION BY PROTECTING ENDOTHELIAL CELLS AGAINST OXIDATIVE STRESS INJURY VIA THE MAPK AND NF-KB SIGNALING PATHWAYS

P.075 FACTORS ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN RUSSIAN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM PULMONARY HYPERTENSION REGISTRY
A. Volkov, E. Nikolaeva, T. Martynyuk

P.076 TREATMENT WITH CYCLOPHOSPHAMIDE FOR SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE DOES NOT LEAD TO A SUSTAINED IMPROVEMENT IN LUNG FUNCTION IN TWO INDEPENDENT COHORTS
E. Volkmann, D. Tashkin, M. Sim, N. Li, D. Khanna, M. Roth, P. Clements, A. Hoffmann-Vold, D. Furst, G. Kim, J. Goldin, R. Elshoff

P.077 THE COURSE OF THE FORCED VITAL CAPACITY DURING TREATMENT FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE PREDICTS LONG-TERM SURVIVAL IN 2 INDEPENDENT COHORTS

P.078 LUNG ULTRASONOGRAPHY: POSSIBLE ROLE AS PREDICTOR OF PULMONARY INVOLVEMENT IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS COMPPLICATED BY EITHER INTERSTITIAL LUNG DISEASE OR PULMONARY ARTERIAL HYPERTENSION
E. Tinazzi, F. Confente, G. Tacchella, G. Patuzzo, C. Lunardi

P.079 GENE EXPRESSION OF ARYL HYDROCARBON RECEPTOR IN IMMUNE CELLS IS ASSOCIATED WITH LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
H. Takei, H. Yasuoka, K. Yoshimoto, K. Yamaoka, T. Takeuchi

P.080 SIRT1 (SIRTUIN1) GENE POLYMORPHISM IS ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND DIGITAL ULCERS IN JAPANESE SYSTEMIC SCLEROSIS (SSc)
K. Takagi, Y. Kawaguchi, Y. Ichimura
P.081 PREVALENCE AND PREDICTIVE VALUE OF SYSTEMIC SCLEROSIS-ASSOCIATED ANTIBODIES: AN EASTERN-EUROPEAN SINGLE-CENTER EXPERIENCE
I. Szabo, R. Nichitean, A. Petcu, S. Rednic

P.082 NKX2.5 IS ASSOCIATED TO ENDOMT IN PULMONARY ARTERIAL HYPERTENSION
J. Santos Cade, I. Papaioannou, C. Denton, D. Abraham, M. Ponticos

P.083 FACTORS ASSOCIATED WITH THE 6-MINUTE WALK DISTANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.084 LUNG ULTRASOUND IN ONE-YEAR FOLLOW-UP OF A SSC PATIENT COHORT: IT COULD BE THE ONSET OF ABNORMAL ULTRASOUND SIGNS AN IMPORTANT IMAGING TOOL TO REDUCE THE FREQUENCY OF CHEST TOMOGRAPHIC ASSESSMENT?
C. Rotondo, M. Nivuori, L. Urso, S. Lopriore, G. Lapadula, F. Iannone

P.085 PROGNOSTIC FACTORS FOR SEVERE PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS

P.086 TRANSTHORACIC ECHOCARDIOGRAPHY TO QUANTIFY PULMONARY VASCULAR RESISTANCES IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.087 REPRODUCIBILITY AND UTILITY OF THE 6-MINUTE WALK TEST IN SYSTEMIC SCLEROSIS PATIENTS
G. Pugnet, Z. Marjanovic, C. Deligny, K. Boussardon, I. Benzidia, M. Puyade, P. Lansiaux, E. Vandecasteel, V. Smith, D. Farge

P.088 MONOTHERAPY VERSUS COMBINATION THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH). RETROSPECTIVE COHORT STUDY FROM THE NATIONWIDE SPANISH SCLERODERMA REGISTRY (RESCLE).

P.089 ASSOCIATION OF DIGITAL ULCERS WITH SEVERITY OF LUNG FUNCTION TEST IN SYSTEMIC SCLEROSIS – ASSOCIATED INTERSTITIAL LUNG DISEASE IN FOLLOW UP STUDY
O. Ovsyannikova, O. Koneva, L. Ananieva, L. Garzanova, O. Desinova, M. Starovoytova

P.090 FOLLOW-UP OF PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS

P.091 QUANTITATIVE CT LUNG TEXTURE ANALYSIS IN INTERSTITIAL LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS: A FOLLOW-UP STUDY

P.092 PROGRESSION OF THE LOSS OF DIFFUSING CAPACITY IN SSC OVERLAP SYNDROMES IS MORE PRONOUNCED THAN IN LIMITED SSC - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLERODERMA
P.093  SURVIVAL OF CONNECTIVE TISSUE DISEASE ASSOCIATED TO PULMONARY HYPERTENSION
A.P. Luppino-Assad, F.A.G. Oleas, J.L. Alves, C.V.P. Jardim, P.D. Sampaio-Barros, R. Souza

P.094  CLINICAL PHENOTYPES AND SURVIVAL OF PRE-CAPILLARY PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS

P.095  CORRELATION BETWEEN SKIN SCORE AND PULMONARY INVOLVEMENT IN PATIENTS OF SCLERODERMA-PROSPECTIVE STUDY
J. Kulkarni, S. Singh, R. Mathur

P.096  STUDY MOFETIL MYCOPHENOLATE EFFICACY IN THE PATIENTS WITH SYSTEMIC SCLERODERMA RECEIVING LONG-TERM THERAPY (FOR AT LEAST ONE YEAR)
O. Koneva, O. Ovsyannikova, L. Ananieva, O. Desinova, L. Garzanova, M. Stsrovoytova

P.097  RITUXIMAB EFFICACY IN THE PATIENTS WITH SYSTEMIC SCLERODERMA DIFFERING IN EXTENT OF INTERSTITIAL LUNG DISEASE
O. Koneva, L. Ananieva, O. Desinova

P.098  PULMONARY MANIFESTATIONS OF SCLERODERMA
M. Kechida, N. Lorenzo Villalba, T. Merzouki, R. Klii, S. Hammami, I. Khochtali

P.099  RACIAL DIFFERENCES IN SSC DISEASE PRESENTATION: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP STUDY

P.100  SMOKING BEHAVIOUR AND THE PROGRESSION OF ORGAN MANIFESTATIONS IN SYSTEMIC SCLEROSIS: A LONGITUDINAL EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP STUDY

P.101  PLASMA CXCL4 LEVEL MAY NOT REFLECT THE EFFECTS OF INTRAVENOUS CYCLOPHOSPHAMIDE THERAPY FOR SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Y. Ichimura, Y. Kawaguchi, K. Takagi, A. Tochimoto, T. Higuchi, H. Yamanaka

P.102  TACROLIMUS FOLLOWING INTRAVENOUS CYCLOPHOSPHAMIDE PULSE THERAPY AS AN ALTERNATIVE TREATMENT FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
Y. Ichimura, Y. Kawaguchi, K. Takagi, A. Tochimoto, T. Higuchi, H. Yamanaka

P.103  ASSESSING THE NATURAL HISTORY OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS; RESULTS FROM A COMPLETE, NATIONWIDE COHORT

P.104  CORRELATING PLASMA CYTOKINE LEVELS WITH RIGHT HEART CATHETERIZATION PARAMETERS IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION

P.105  FACTORS ASSOCIATED WITH DETERIORATION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS WITH ANTI-TOPOISOMERASE I ANTIBODY
Y. Yoshimura, T. Matsushita, Y. Hamaguchi, T. Takehara

P.106  DESCRIPTION AND PROGNOSIS FACTORS OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE OUTCOME ON SERIAL HRCT

P.107  SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR C IS ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS

P.108  TO EVALUATE PULMONARY INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS IN THE DAILY PRACTICE
M.A. Cusa, J.I. Enghelmayer, M.E. Fonrouge, S. Scarafia, M.A. Lázaro
PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION

P.109  SERUM PROTEOMIC PROFILE IDENTIFIES NEW BIOMARKERS ASSOCIATED WITH SYSTEMIC SCLEROSIS
A. Ceribelli, M. De Santis, E. Generali, N. Isailovic, M. Caprioli, G.M. Guidelli, C.F. Selmi

P.110  INTERSTITIAL LUNG DISEASE IS INDEPENDENTLY ASSOCIATED WITH INCREASED FECAL CALPROTECTIN LEVELS IN SYSTEMIC SCLEROSIS

P.111  THE SCREENING OF PULMONARY ARTERIAL HYPERTENSION IN SCLERODERMA PATIENTS USING THE DETECT ALGORITHM IN CLINICAL PRACTICE: RESULTS FROM A SINGLE ITALIAN CENTRE
L. Urso, F. Cacciapaglia, E. Praino, S. Lopriore, C. Rotondo, E. De Tommaso, C. D'Agostino, F. Iannone

P.112  SAFETY AND EFFICACY OF INTRAVENOUS VERSUS ORAL CYCLOPHOSPHAMIDE (Cyc) IN THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc) RELATED ILD AND SKIN INVOLVEMENT

P.113  EARLY DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: A SINGLE CENTRE EXPERIENCE WITH DETECT ALGORITHM

P.114  ANTFIBROTIC EFFECTS OF NINTEDANIB IN LUNG FIBROBLASTS ISOLATED FROM PATIENTS WITH SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE
G. Bogatkevich, I. Atanelishvili, T. Akter, A. Noguchi, L. Wollin, R. Silver

P.115  THE HISTONE DEMETHYLASE JUMONJI DOMAIN-CONTAINING PROTEIN 3 (JMJD3) AS CENTRAL MEDIATOR OF FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS (SSc)

P.116  SYSTEMIC SCLEROSIS IN TUNISIA: A MONOCENTER STUDY OF 118 PATIENTS
M. Tougorti, T. Ben Salem, M. Lamloum, I. Ben Ghorbel, M.H. Houman

P.117  INTERSTITIAL LUNG INVOLVEMENT AND MICROVACULATURE CHANGES IN SYSTEMIC SCLEROSIS: A FOLLOW-UP STUDY
R. Becvar, M. Tomcik, S. Skacelova, J. Stork, A. Slovakova

P.118  CAN IMPLEMENTATION OF THE DETECT ALGORITHM IN A SYSTEMIC SCLEROSIS POPULATION ALREADY FOLLOWED WITH YEARLY ECHOCARDIOGRAPHY IDENTIFY ADDITIONAL PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION?
J. Baumgartner-Nielsen, S. Mellemkjær, A. Braae Olesen

P.119  MMP-10, A NOVEL MEDIATOR OF VASCULAR REMODELING UNDERLYING PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS

P.120  THE FREQUENCY OF OBSTRUCTIVE SLEEP APNEA SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS
D. Arslan Tas, K. Aslan, I. Turk, D. Kurt Gok, C.E. Cagliyan, I. Hanta

P.121  QUANTITATIVE CHEST CT PREDICTS 5-YEARS-MORTALITY IN SYSTEMIC SCLEROSIS

CARDBIC

P.122  PROGNOSTIC VALUE OF VENTRICULAR-ARTERIAL FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS
E. Zanatta, E. Beccegato, P. Polito, M. Felicetti, E. Pigatto, G. Famoso, F. Cozzi, F. Tona

P.123  ELECTROCARDIOGRAPHIC FINDINGS IN SYSTEMIC SCLEROSIS ARE VERY SIMILAR TO THOSE OF HEALTHY INDIVIDUALS: DATA FROM THE CANADIAN SCLERODERMA RESEARCH GROUP
S. Wojcik, C. Galatas, T. Huynh, L. Iacoviello, M. Wang, M. Hudson, M. Baron
P.124 WITHDRAWN

P.125 ASSESSMENT OF LEFT VENTRICULAR DIASTOLIC FUNCTION IN A LARGE UNSELECTED SYSTEMIC SCLEROSIS (SSC) COHORT

P.126 EPICARDIAL ADIPOSE TISSUE THICKNESS IN WOMEN WITH SYSTEMIC SCLEROSIS

P.127 ECHOCARDIOGRAPHY IN DETECTION OF PRIMARY SYSTEMIC SCLEROSIS CARDIAC DISEASE
L. Ross, S. Patel, W. Stevens, C. Rabusa, M. Wilson, N. Ferdowsi, G. Strickland, S. Proudman, D. Prior, M. Nikpour

P.128 THE ROLE OF CARDIAC MRI IN SYSTEMIC SCLEROSIS: A FOLLOW-UP STUDY IN SYMPTOMATIC PATIENTS

P.129 CARDIOVASCULAR MORTALITY AT 5 YEARS IN A SINGLE CENTRE COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS AND DIGITAL ULCERS
S. Mazzuca, C. Pintaudi, R. Cimino

P.130 RESCUE FROM FATAL CARDIAC FIBROSIS IN SYSTEMIC SCLEROSIS- NOVEL INSIGHTS: TRAFFICKING TGF-BETA/ FRA2-DEPENDENT AUTOPHagy
M. Stellato, M. Rudnik, F. Renoux, E. Pachera, K. Sotlar, K. Klingel, J. Henes, P. Blyszczuk, O. Distler, G. Kania

P.131 FRAGMENTED QRS PATTERNS DO NOT CORRELATE WITH THE DEGREE OF LUNG AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
D. Saygin, C. Saygin, M. Kostek, M. Ozdemir, T. Torun, S. Altay, G. Hatemi

P.132 GLOBAL LONGITUDINAL STRAIN AS EARLY PREDICTOR OF SYSTOLIC DYSFUNCTION. ANALYSIS IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
C. Fischetti, F. Guerra, A. Ferrarini, L. Zuliani, M.G. Danieli, P. Fraticelli, G. Pomponio, A. Capucci, A. Gabrielli

P.133 IMPLANTABLE LOOP RECORDER IN SYSTEMIC SCLEROSIS OVER 3 YEARS CONFIRMS INCIDENTAL SIGNIFICANT ARHYTHMIAS AND SUGGESTS CMR AND CARDIAC BIOMARKER ASSOCIATION

P.134 SYMPTOMATIC CORONARY ARTERY DISEASE IN SYSTEMIC SCLEROSIS COMPARED WITH TYPE 2 DIABETES MELLITUS IN FEMALE PATIENTS: A CROSS-SECTIONAL STUDY

P.135 SYSTEMIC SCLEROSIS, A NEW CAUSE OF HIGH CARDIAC OUTPUT? ABOUT 4 CASES
E. Chatelus, M. Canuet, P.M. Duret, J. Sibilia, J.E. Gottenberg

P.136 CARDIAC INVOLVEMENTS IN SYSTEMIC SCLEROSIS
M. Tougorti, T. Ben Salem, I. Ben Ghorbel, M. Lamloum, M.H. Houman

P.137 ECHOCARDIOGRAPHY FOR THE ASSESSMENT OF CARDIOVASCULAR BURDEN IN SYSTEMIC SCLEROSIS: AN EUSTAR CENTER EXPERIENCE
C. Ancuta, C. Pomirleanu, C. Pau, E. Ancuta, R. Chirieac, F. Mitu

P.138 SYSTEMIC SCLEROSIS–RHEUMATOID ARTHRITIS OVERLAP SYNDROME. DESCRIPTION OF 10 INCIDENTS

P.139 INTERLEUKIN-17 AND INTERLEUKINE-23 PROFILE AND CLINICAL ASSOCIATION IN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Zekovic, N. Damjanov
OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

P.140  THE ASSOCIATION OF SOCIODEMOGRAPHIC AND DISEASE VARIABLES WITH HAND FUNCTION IN SYSTEMIC SCLEROSIS: A SCLERODERMA PATIENT-CENTERED INTERVENTION (SPIn) COHORT STUDY

P.141  CAUSES AND PREDICTORS OF MORTALITY IN SYSTEMIC SCLEROSIS IN SOUTH AFRICANS
M. Tikly, C. Ickinger, Z. Dire

P.142  THE VALIDATION OF COCHIN HAND FUNCTIONAL SCALE QUESTIONNAIRE IN TURKISH SPEAKING PATIENTS WITH SYSTEMIC SCLEROSIS
D. Temiz Karadag, S. Tekeoglu, O. Ozdemir Isik, A. Yazicioglu, A. Cefle

P.143  WITHDRAWN

P.144  CYTOKINE/GROWTH FACTORS MULTIPLEX ASSAY REFLECTS/IDENTIFIES PHENOTYPIC VARIATIONS AMONG SCLERODERMA PATIENTS
Y. Suliman, S. Kafaja, M.F. Alemam, I. Valera, J. Grotts, D.E. Furst

P.145  HUMANISTIC AND COST BURDEN OF SYSTEMIC SCLEROSIS: A REVIEW OF THE LITERATURE
A. Fischer, E. Zimovetz, C. Ling, D. Esser, N. Schoof

P.146  CLINICAL CHARACTERISATION OF 133 ADULTS WITH LINEAR MORPHEA; COMPARING PAEDIATRIC AND ADULT ONSET DISEASE
A. Saracino, C. George, V. Ong, C. Fonseca, C. Orteu, C. Denton

P.147  SIGNIFICANT IMPACT OF SKIN DISEASE IN SYSTEMIC SCLEROSIS AND PATIENT PERCEIVED BENEFITS OF SPECIALIST DERMATOLOGY INPUT
A. Saracino, A. Mizara, V. Ong, C. Denton

P.148  SYSTEMIC SCLEROSIS - A 12 YEARS RETROSPECTIVE STUDY OF AN INTERNAL MEDICINE (AUTOIMMUNE DISEASES) AND RHEUMATOLOGY APPOINTMENTS IN A SMALL HOSPITAL CENTRE
A. Sanches, R. Assis, S. Martins, J. Madruga, J. Garcia, M. Carvalho

P.149  HIGH FREQUENCY OF CANCER IN A LARGE BRAZILIAN COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
P. Sampaio-Barros, A. P. Luppino-Assad, H. Silva, D. Andrade

P.150  THE ROLE OF INFLAMMATORY MARKERS IN ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS

P.151  CHALLENGES AND SERVICE PREFERENCES OF INFORMAL CAREGIVERS OF PEOPLE WITH SYSTEMIC SCLEROSIS

P.152  NOMINAL TECHNIQUE FOCUS GROUPS TO EXPLORE THE CHALLENGES AND SUPPORT PREFERENCES OF INFORMAL CAREGIVERS OF PEOPLE WITH SCLERODERMA

P.153  SURVIVAL AND PROGNOSIS FACTORS IN SYSTEMIC SCLEROSIS: DATA OF A FRENCH MULTICENTER COHORT OF INCIDENT PATIENTS, SYSTEMATIC REVIEW AND META- ANALYSIS OF THE LITERATURE

P.154  REASONS FOR ATTENDING SUPPORT GROUPS AND ORGANIZATIONAL PREFERENCES: THE NORTH AMERICAN SUPPORT GROUP SURVEY

P.155  IMPACT OF STANDARDIZED TRAINING ON ACCURACY OF THE MODIFIED RODNAN SKIN SCORING (MRSS) IN SYSTEMIC SCLEROSIS (SSC)

P.156  PREVALENCE, SEVERITY AND CLINICAL SIGNIFICANCE OF PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS
P. Ostojic, N. Djurovic, B. Stojic, S. Knezevic-Apostolski, D. Bartolovic

P.157  PERFORMANCE OF THE 2016 REVISED EUSTAR ACTIVITY INDEX FOR SYSTEMIC SCLEROSIS IN A SINGLE-CENTER COHORT
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.159</td>
<td>Quantifying the Burden of Systemic Scleroderma: A Data Linkage Study</td>
<td>K. Morrisroe, W. Stevens, J. Sahhar, G-S. Ngian, C. Rabusa, N. Ferdowsi, S. Proudman, M. Nikpour</td>
</tr>
<tr>
<td>P.162</td>
<td>Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients with Systemic Scleroderma</td>
<td>C. March, D. Huscher, E. Preis, A. Makowka, F. Buttgereit, G. Riemekasten, K. Norman, E. Siegert</td>
</tr>
<tr>
<td>P.163</td>
<td>Burden of Illness of Systemic Scleroderma Among Commercially Insured Patients</td>
<td>Z. Zhou, Y. Yu, W. Tang, X. Liu, Z. Zhou, D. Macaulay, A. Fischer</td>
</tr>
<tr>
<td>P.164</td>
<td>Important Topics Not Discussed during Systemic Sclerosis Consultations: Impact on Patients and Caregivers</td>
<td>C.P. Denton, B. Laird, L. Moros, J.L. Luna Flores</td>
</tr>
<tr>
<td>P.165</td>
<td>Challenges in Physician-Patient Communication Limit Patient Understanding and Support in Systemic Sclerosis with Interstitial Lung Disease (SSC-ILD)</td>
<td>C.P. Denton, B. Laird, L. Moros, J.L. Luna Flores</td>
</tr>
<tr>
<td>P.166</td>
<td>The Assessment of Exposure to Inorganic Particles: Implementing the Same Questionnaire in a Nation-Wide Survey (N=2 739) and on a Specific Sample of SSC Patients from a Regional Referral Center</td>
<td>C. Cavalin, A. Lescoat, A. Ballerie, O. Macchi, M. Catinon, C. Chemarin, M. Vincent, Pa. Rosental, P. Jégo</td>
</tr>
<tr>
<td>P.167</td>
<td>Health Status and Quality of Life of Patients with Systemic Scleroderma in 2017</td>
<td>M. Lacoste, S. Palat, K. Ly, G. Gondran, E. Liozon, E. Le Cousturnier, H. Bezanahary, A. Fauchais</td>
</tr>
<tr>
<td>P.168</td>
<td>The Course of Mouth Opening and Its Relationship with Disease Characteristics, Global Functioning, Quality of Life and Mouth Handicap in Systemic Sclerosis</td>
<td>S.J.H. Khidir, M. Boonstra, G.W.M. Boerrigter, E.M. Voogt van der Harst, S.A. Bergstra, N. Ajmone Marsan, M.K. Ninaber, T.W.J. Huizinga, J.K. de Vries-Bouwstra</td>
</tr>
<tr>
<td>P.171</td>
<td>A Psychosocial Model of Quality of Life in Iranian Patients with Systemic Sclerosis: A 12-Month Longitudinal Study</td>
<td>H. Kavosi, A. Javinani, Sh. Mostafaei, Ar. Jamshidi, R. Atef Yekta, M. Mahmoudi, A. Kazemnejad, F. Gharibdoost</td>
</tr>
</tbody>
</table>
OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

P.175 EXPERT CONSENSUS ON THE ANNUAL SYSTEMIC INVESTIGATION OF ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS
A. Hoffmann-Vold, O. Distler, O. Kowal-Bielecka, D. Khanna, Y. Allanore

P.176 IMMUNOGENICITY AND SAFETY OF PNEUMOCOCCAL VACCINATION IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.177 MANAGEMENT OF PULMONARY HYPERTENSION IN SCLERODERMA: ARE WE IN COMPLIANCE WITH THE RECOMMENDATIONS? OUR EXPERIENCE IN INTERNAL MEDICINE
D. Hakem, N. Slimani, A. Berrah

P.178 PATIENT EDUCATION AUGMENTED SELF EFFICACY IN PATIENTS WITH SYSTEMIC SCLEROSIS
K. Gunnarsson, A. Nordin

P.179 LATE-ONSET SYSTEMIC SCLEROSIS - EXPERIENCE OF A EUSTAR CENTER

P.180 DIAGNOSIS OF SYSTEMIC SCLEROSIS -“A TANGLED STORY”

P.181 DETERMINANTS OF LIFE QUALITY IN SYSTEMIC SCLEROSIS AND PATIENT PERCEPTION OF THE DISEASE

P.182 MEAN NUMBER OF CAPILLARIES PREDICTS DISEASE ACTIVITY AT 6 MONTHS FOLLOW-UP

P.183 ASSESSING SURVIVAL, CAUSES OF DEATHS AND PREDICTORS OF MORTALITY IN SYSTEMIC SCLEROSIS; RESULTS FROM A COMPLETE, NATIONWIDE COHORT

P.184 OUTCOMES OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS: A EUSTAR DATABASE STUDY.

P.185 CLINICAL CHARACTERISTICS AND MORTALITY RATE FOR THAI ELDERLY ONSET SYSTEMIC SCLEROSIS
C. Foocharoen, R. Apiptattarakul, S. Netwijitpan, A. Mahakanukrauh, S. Suwannaroj, P. Limpawattana, R. Nanagara

P.186 PROPOSAL FOR A JUVENILE SYSTEMIC SCLEROSIS RESPONSE INDEX(JSSCRI): RESULT OF THE CONSENSUS MEETING IN HAMBURG. GERMANY 11TH OF DECEMBER 2016

P.187 ASSESSING THE PREVALENCE OF JUVENILE SYSTEMIC SCLEROSIS IN CHILDHOOD USING ADMINISTRATIVE CLAIMS DATA FROM THE UNITED STATES
I. Foeldvari, T. Beukelman, F. Xie

P.188 IS THERE A DIFFERENCE IN THE CLINICAL PRESENTATION OF JUVENILE SYSTEMIC SCLERODERMA PATIENTS ACCORDING THE AGE OF ONSET: RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERM

P.189 ARE PATIENTS WITH OVERLAP FEATURES DIFFERENT FROM PATIENTS WITHOUT? RESULTS FROM THE JUVENILE SYSTEMIC SCLERODERMA COHORT (WWW.JUVENILE-SCLERODERM.COM)
5TH SYSTEMIC SCLEROSIS WORLD CONGRESS

OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

P.190 MALE PATIENTS HAVE A MORE SEVERE COURSE AS FEMALE PATIENTS WITH DIFFUSE JUVENILE SYSTEMIC SCLERODERMA? RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT WWW.JUVENILE-SCLERODERMA.COM

P.191 UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT PROJECT. CHARACTERISTICS OF THE FIRST 97 PATIENTS AT FIRST ASSESSMENT WWW.JUVENILE-SCLERODERMA.COM

P.192 CHANGES IN CAUSES OF DEATH IN SYSTEMIC SCLEROSIS: 1995-2015: DATA FROM EUSTAR NETWORK

P.193 THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) SCORE – A NEW PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SYSTEMIC SCLEROSIS – PRELIMINARY RESULTS FROM THE ONGOING VALIDATION STUDY

P.194 NORMALIZATION OF ACR CRISP NUMERATOR FOR BASELINE DATA OFFERS A MEASURE OF MAGNITUDE OF RESPONSE: RESULTS FROM A REAL-LIFE OBSERVATIONAL STUDY
G. Abignano, J. Blagojevic, G. Bagnato, S. Eng, M. Buch, P. Emery, F. Del Galdo

P.195 FACTORS INFLUENCING PATIENT INTEREST IN PARTICIPATING IN AN ONLINE SELF-CARE INTERVENTION: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT STUDY

P.196 HIGH-THROUGHPUT QUANTITATIVE HISTOLOGY IN SYSTEMIC SCLEROSIS SKIN DISEASE USING COMPUTER VISION

P.197 CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS PRESENTING ANTI PM-SCL ANTIBODIES IN AN INTERNAL MEDICINE UNIT
G. Chalhoub

P.198 CAREGIVER, CARE RECIPIENT, AND CAREGIVING FACTORS ASSOCIATED WITH SYMPTOMS OF DEPRESSION AMONG INFORMAL CAREGIVERS OF PEOPLE LIVING WITH SYSTEMIC SCLEROSIS

P.199 ACUTE HOSPITAL ADMISSIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS
J. Caetano, L. Boavida, M. Amaral, S. Oliveira, J.D. Alves

P.200 MENTAL HEALTH CARE IN SYSTEMIC SCLEROSIS: RATES OF UTILIZATION AND ASSOCIATED FACTORS IN THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT

P.201 SKIN BIOPSIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: A RETROSPECTIVE COHORT STUDY
I. Atzeni, A. Eman Abdulle, J. Westra, A.J. Stel, D.J. Mulder

P.202 MANAGING SYSTEMIC SCLEROSIS: ASSESSING THE EDUCATIONAL NEEDS OF RHEUMATOLOGISTS
Z. Ahmad, S. Johnson

P.203 CORRELATION OF THE AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE INDEX IN SYSTEMIC SCLEROSIS WITH SERUM BIOMARKERS OF FIBROGENESIS IN AN OBSERVATIONAL COHORT
G. Abignano, J. Blagojevic, S. Eng, M. Buch, P. Emery, D. Khanna, F. Del Galdo
IMAGING

P.204 A RETROSPECTIVE STUDY OF PATIENTS WITH SYSTEMIC SCLERODERMA IN A GENERAL HOSPITAL IN NORTHWESTERN GREECE

P.205 LASER SPECKLE CONTRAST ANALYSIS, A PROMISING TOOL TO EVALUATE PERIPHERAL FLOW IN SYSTEMIC SCLEROSIS

P.206 STUDY TO INVESTIGATE THE RELATIONSHIP BETWEEN CAPILLAROSCOPY STAGE AND ORGAN INVOLVEMENT
P. Traill, J. Golla, C. Baines, S. Bhat

P.207 CRITERION VALIDITY OF ULTRASOUND IMAGING IN CHARACTERIZATION OF SKIN ULCERS IN SCLERODERMA
Y. Suliman, S. Kafaja, Y. Tawfik, I. Valera, D. Furst

P.208 A RETROSPECTIVE STUDY OF PATIENTS WITH SYSTEMIC SCLERODERMA IN A GENERAL HOSPITAL IN NORTHWESTERN GREECE

P.209 NAILFOLD CAPILLAROSCOPY FEATURES PREDICTING TRANSITION FROM UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE INTO “SCLERODERMA SPECTRUM DISORDERS”
M. Meroni, M. Parodi, P. Rossi, P. Stobbione

P.210 DERMOSCOPY VERSUS VIDEOCAPILLAROSCOPY IN THE ASSESSMENT OF NAILFOLD CAPILLAROSCOPY IMAGES IN PATIENTS WITH SYSTEMIC SCLEROSIS AND HEALTHY CONTROLS

P.211 QUANTIFYING THE RANGE OF NORMALITY IN NAILFOLD CAPILLARIES: COMPARING DENSITY AND WIDTH BETWEEN HEALTHY CONTROL AND SSC POPULATIONS

P.212 THE PROGNOSTIC VALUE OF NAILFOLD CAPILLAROSCOPY IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW
D. Paxton, J.D. Pauling

P.213 FEASIBILITY STUDY OF MEASUREMENT OF OXYGENATION IN NAILFOLD CAPILLARIES IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO HEALTHY CONTROLS

P.214 NAILFOLD CAPILLAROSCOPY PICTURES MODIFICATIONS DURING PREGNANCY IN A CONNECTIVE TISSUE DISEASES COHORT
M. Meroni, P. Rossi, M. Parodi, P. Stobbione

P.215 NAILFOLD CAPILLAROSCOPY PICTURES MODIFICATIONS DURING PREGNANCY IN A CONNECTIVE TISSUE DISEASES COHORT
M. Meroni, P. Rossi, M. Parodi, P. Stobbione

P.216 CLINICAL AND ULTRASONOGRAPHIC EVALUATION OF JOINT AND TENDON INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
M.V. Martire, P. Marcaida, S. Scarafia, G. Crespo, A. Secco, M. Marmo

P.217 INHOMOGENEITY OF CAPILLAROSCOPIC CHANGES IN SYSTEMIC SCLEROSIS – PRACTICAL IMPLICATIONS
S. Lambova, U. Müller-Ladner

P.218 USING TRANSITIONAL CHANGES ON HRCT TO ASSESS THE IMPACT OF TREATMENT WITH CYCLOPHOSPHAMIDE OR MYCOPHENOLATE ON SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE FROM SCLERODERMA LUNG STUDY II

P.219 IMAGING CALCINOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS BY RADIOGRAPHY, COMPUTERISED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING
M. Hughes, R. Hodgson, J. Harris, N. Porter, S. Jackson, J. Manning, T. Moore, S. Peytrignet, C. Hutchinson, T. Cootes, A. Herrick
IMAGING

P.220 AUTOMATED ANALYSIS OF NAILFOLD IMAGES FROM HANDHELD DEVICES

P.221 ARTHRALKIAS ARE PREDICTIVE FACTORS OF FOOT INVOLVEMENT EVALUATED BY ULTRASONOGRAPHY IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROSPECTIVE STUDY
G. Cuomo, C. Romano, M. Zappia, L.E. Adinolfi

P.222 18F-FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY/ COMPUTER TOMOGRAPHY (PET/CT) SCAN AND LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC): WHICH IS THE FUTURE?
S. Bellando Randone, L. Tartarelli, E. Cavigli, S. Guiducci, C. Bruni, G. Lepri, C.M. Mihai, O. Distler, A. Pupi, M. Matucci Cerinic

P.223 CONE BEAM COMPUTED TOMOGRAPHY (CBCT) FOR THE ASSESSMENT OF ORAL MANIFESTATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY RESULTS OF AN EUSTAR COHORT
C. Ancuta, C. Pomirleanu, M. Antohe, E. Ancuta, R. Chirieac, C. Iordache

VASCULAR

P.224 ARE EXTREMITY TELANGIECTASES RELATED TO SEVERE DISEASE IN SYSTEMIC SCLEROSIS?

P.225 CHARACTERISTICS AND CAPILLAROSCOPIC FINDINGS OF SYSTEMIC SCLEROSIS PATIENTS WITH SEVERE PERIPHERAL VASCULAR INVOLVEMENT RECEIVING SPECIFIC VASODILATOR TREATMENT

P.226 ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS
E. Wielosz, M. Majdan, M. Dryglew ska, A. Górak

P.227 ABNORMAL NAILFOLD CAPILLAROSCOPY PATTERN IS COMMON IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND ASSOCIATED WITH ORGAN INVOLVEMENT

P.228 NAILFOLD CAPILLARY MICROSCOPY AND LOW BODY MASS INDEX IN RAYNAUD’S PHENOMENON PATIENTS

P.229 CLINICAL CHARACTERISTICS OF CRITICAL LIMB ISCHEMIA IN SYSTEMIC SCLEROSIS
Y. Shirai, Y. Okazaki, M. Kuwana

P.230 ENDOTHELIAL DYSFUNCTION MARKERS AS CANDIDATES FOR DISEASE ACTIVATION BIOMARKERS

P.231 ASSOCIATION BETWEEN OXYGEN DELIVERY TO TISSUES AND SKIN ULCERS IN SYSTEMIC SCLEROSIS
A. Sari, Y.Z. Sener, M. Oksul, B. Armagan, A. Erden, L. Kilic, A. Akdogan

P.232 RAYNAUD’S PHENOMENON AND ITS IMPACT ON ACTIVITIES IN DAILY LIFE DURING ONE YEAR OF FOLLOW-UP IN EARLY SYSTEMIC SCLEROSIS
G. Sandqvist, A. Scheja, M. Wildt, R. Hesselstrand

P.233 CORRELATIONS BETWEEN CHOROIDAL THICKNESS AND SKIN BLOOD PERFUSION IN SYSTEMIC SCLEROSIS PATIENTS, BEFORE AND AFTER ILOPROST TREATMENT
A. Sulli, B. Ruar o, S. Paolino, M. Nicolo’, C. Pizzorni, C.E. Traverso, C.A. Cutolo

P.234 CORRELATION BETWEEN CAPILLAROSCOPY PATTERNS OF MICROANGIOPATY AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS
B. R uaro, A. Sulli, C. Pizzorni, S. Paolino, M. Ghio, E. Alessandri, M. Cutolo

P.235 ON-DEMAND SILDENAFIL AS A TREATMENT FOR RAYNAUD’S PHENOMENON: A SERIES OF N-OF-1 TRIALS

P.236 NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS IN SCLERODERMA SPECTRUM DISORDERS
V. Rodrigues Bernardino, M. Fernandes, Ac. Rodrigues
VASCULAR

P.237 NAILFOLD VIDEOCAPILLAROSCOPY SCLERODERMA PATTERN IN PATIENTS WITHOUT CONNECTIVE TISSUE DISORDERS
V. Rodrigues Bernardino, M. Fernandes, Ac. Rodrigues

P.238 LEPTIN AND ADIPONECTIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS: CORRELATION WITH MANIFESTATIONS OF VASCULAR DAMAGE

P.239 SURVIVAL IN SYSTEMIC SCLEROSIS-ASSOCIATED DIGITAL ULCERS. META-ANALYSES AND SYSTEMATIC REVIEW OF THE LITERATURE

P.240 RELIABILITY OF SIMPLE CAPILLAROSCOPIQUE DEFINITIONS TO DESCRIBE CAPILLARY MORPHOLOGY IN RHEUMATIC DISEASES

P.241 ULTRASONIC-ASSISTED WOUND DEBRIDEMENT COMPARED WITH AUTOLITIC DEBRIDEMENT FOR SCLERODERMA ULCERS: A RETROSPECTIVE CLINICAL STUDY IN A HETEROGEOUS POPULATION OF SYSTEMIC SCLEROSIS PATIENTS
A. Marcoccia, C. Salvucci, T. D'Alesio, T. Nuzzo, M.G. Modesti

P.242 COMBINATION OF CAPILLAROSCOPIC AND ULTRASONOGRAPHIC EVALUATIONS IN SYSTEMIC SCLEROSIS: RESULTS OF A CROSS-SECTIONAL STUDY
A. Lescoat, G. Coiffier, M. de Carlan, C. Cazalets, A. Ballerie, C. Droicourt, A. Perdriger, P. Jégo

P.243 ASSOCIATION OF SKIN PIGMENTATION DISORDERS WITH VASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS: ANALYSIS OF A COHORT OF 239 PATIENTS

P.244 EVALUATION OF NAILFOLD CAPILLAROSCOPIQUE PATTERN AND CAPILLARY DENSITY IN 318 PATIENTS WITH CONNECTIVE TISSUE DISEASES
G. Kumánovics, G. Nagy, L. Czirják

P.245 COMPARATIVE EFFICACY OF TREATMENTS FOR SECONDARY RAYNAUD'S PHENOMENON: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED TRIALS

P.246 WHOLE BODY DISTRIBUTION AND CLINICAL ASSOCIATIONS OF TELANGIECTASIA IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY

P.247 SAFETY AND EFFECTIVENESS OF HYPERBARIC OXYGEN THERAPY FOR SYSTEMIC SCLEROSIS ULCERS
S. Armstrong, A. Evans, Z. Ahmad, S. Johnson

P.248 VENOUS THROMBOEMBOLISM IN SYSTEMIC SCLEROSIS: PREVALENCE, RISK FACTORS AND IMPACT ON SURVIVAL
S. Johnson, N. Hakami, Z. Ahmad, D. Wijeysundera

P.249 A FEASIBILITY STUDY OF A NOVEL LIGHT TREATMENT FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS

P.250 A STUDY EXAMINING THE RELIABILITY OF DIGITAL ULCER DEFINITIONS AS PROPOSED BY THE UK SCLERODERMA STUDY GROUP: CHALLENGES AND INSIGHTS FOR FUTURE CLINICAL TRIAL DESIGN

P.251 STUDY OF QUANTITATIVE VIDEOCAPILLAROSCOPY IN SYSTEMIC SCLEROSIS

P.252 ENDOTHELIAL DYSFUNCTION AND CORTICOSTEROID THERAPY IN PATIENTS WITH SCLERODERMA
J.J. Gonzalez, P. Garcia De La Peña, O. Carrión, A. Abdelkader

P.253 SUBCLINICALATHEROMATOSIS AND VITAMIN D DEFICIENCY IN PATIENTS WITH SCLERODERMA
J.J. Gonzalez, P. García De La Peña, O. Carrión, A. Abdelkader
**VASCULAR**

**P.254 INTRAVENOUS EPOPROSTENOL AS TREATMENT FOR DIGITAL VASCULOPATHY ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASES**
H. Farber, S. Law, R. Simms

**P.255 THE ROLE OF NAILFOLD CAPILLAROSCOPY IN THE STUDY OF RAYNAUD’S PHENOMENON - EXPERIENCE IN A MEDICAL CENTER IN ARGENTINA**
S. Scarafia, M.A. Cusa

**P.256 DIFFERENTIAL DIAGNOSIS OF NECROTIC DIGITAL ULCERS MANAGED IN THE LAST 7 YEARS IN AN INTERNAL MEDICINE UNIT: A PROPOS 14 PATIENTS**
G. Chalhoub

**P.257 A COHORT STUDY OF MACROVASCULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS**
C. Caimmi, S. De Marchi, G. Astorino, E. Bertoldo, P. Caramaschi, M. Rossini

**P.258 SEVERE SYSTEMIC SCLEROSIS AND NAILFOLD MICROANGIOPATHY**
M. Boonstra, D.C. Noordhoek, T.W.J. Huizinga, L.J.J. Beart van de Voorde, J.K. de Vries-Bouwstra

**P.259 CORRELATION BETWEEN HEALING TIME AND BLOOD PERFUSION BY LASER SPECKLE CONTRAST ANALYSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS**
S. Barsotti, A. D’Ascanio, V. Venturini, L. Amanzi, S. Bilia, M. Mosca, A. Della Rossa

**P.260 RAYNAUD’S PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH PROSTANOIDs**
Z. Bagautdinova, I. Gaisin

**P.261 ASSOCIATION BETWEEN BONE DENSITY AND MICROARCHITECTURE AND MACRO- AND MACRO-VASCULAR IMPAIRMENTS AT THE HAND IN SYSTEMIC SCLEROSIS**
L. Atlan, N. Ibrahim, A. Valery, C. Bazzi, F. Rollin, G. Bens, M. Marot, E. Esteve, E. Lespessailles

**P.262 CAPILLAROSCOPIC FINDINGS IN PATIENTS WITH INCOMPLETE CREST SYNDROME: PRELIMINARY RESULTS**
C. Pomirleanu, R. Păiu, E. Ancuta, R. Chirieac, C. Ancuta

**P.263 SUBCLINICAL ATHEROSCLEROSIS IS LOWER IN PATIENTS WITH SYSTEMIC SCLEROSIS THAN IN PATIENTS WITH RHEUMATOID ARTHRITIS**

**P.264 CAPILLAROSCOPY AND MACROVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS**

**P.265 FACTORS RELATED WITH THE DEVELOPMENT OF ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS**

**P.266 STUDY OF THE ROLE OF IL-6 IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS**

**P.267 IMPLICATIONS OF CAPILLAROSCOPIC PATTERNS ON CLINICAL MANIFESTATIONS AND PROGNOSIS IN THE SPANISH REGISTRY OF SYSTEMIC SCLEROSIS PATIENTS (RESCLE)**
M. Rodero

**RENAI**

**P.268 ROLE OF COMPLEMENT IN SCLERODERMA RENAL CRISIS**
MUSCULOSKELETAL SYSTEM & REHABILITATION

P.269 AN EXPLORATIVE STUDY EVALUATING FEASIBILITY AND EFFECTIVENESS OF TWO DIFFERENT EXERCISE PROGRAMS IN SYSTEMIC SCLEROSIS ASSOCIATED MICROSTOMIA
E. Sydow, S. Arat, G. Nijs, S. Severi, R. Westhovens, J. Lenaerts, E. De Langhe

P.270 PRELIMINARY DATA OF AN INTENSIVE PHYSIOTHERAPY PROGRAMME FOR INDIVIDUALS WITH SYSTEMIC SCLEROSIS - SINGLE-CENTER CONTROLLED STUDY

P.271 SIGNIFICANCE OF COMBINED ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR IN A NEW ZEALAND COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
K. Solanki, S. Kamalaksha, D.H.N. White

P.272 FREQUENCY AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS POSITIVE FOR ANTIBODIES TO RIBONUCLEOPROTEIN
R. Shayakhmetova, L. Ananieva, O. Koneva, M. Starovoitova, O. Desinova, O. Ovsyannikova

P.273 PANNICULITIS OCCURRING IN SYSTEMIC SCLEROSIS: A REPORT OF 17 CASES FROM A LARGE UK SYSTEMIC SCLEROSIS COHORT
A. Saracino, P. Fiandeiro, S. Nihtyanova, V. Ong, C. Orteu, C. Denton

P.274 PERIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS
P. Sampaio-Barros, J. Teixeira, S. Gavinier, A. P. Luppino-Assad, H. Silva, D. Andrade

P.275 IMPAIRED MUSCLE FUNCTION AND SHOULDER-ARM MOVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
H. Pettersson, C. Boström, R. Walle-Hansen, L. Jakobsson, E. Svenungsson, A. Nordin, H. Alexanderson

P.276 CHANGES OF BODY COMPOSITION IN SCLERODERMA PATIENTS – DECREASED LEAN BODY MASS, BODY FAT AND BONE MINERAL DENSITY ARE ASSOCIATED WITH DISEASE ACTIVITY AND PHYSICAL ACTIVITY

P.277 FUNCTIONAL IMPACT OF MUSCULOSKELETAL INVOLVEMENT DETECTED BY US EVALUATION IN THE HAND OF SYSTEMIC SCLEROSIS PATIENTS: A TRANSVERSAL STUDY ON 67 PATIENTS
G. Coiffier, A. Lescoat, A. Ballerie, C. Cazalets, C. Droitcourt, N. Belhomme, I. Bonan, A. Perdriger, P. Jégó

P.278 MUSCULOSKELETAL INVOLVEMENT ASSESSED BY PDUS IN SYSTEMIC SCLEROSIS: RESULTS OF A CROSS-SECTIONAL STUDY ON 102 PATIENTS AND ASSOCIATIONS WITH THE MAIN CLINICAL CHARACTERISTICS OF THE DISEASE
A. Lescoat, A. Ballerie, C. Cazalets, N. Belhomme, C. Droitcourt, A. Perdriger, P. Jégó, G. Coiffier

P.279 A HOME BASED PROGRAM FOR HANDS IN SYSTEMIC SCLEROSIS
S. Landim, M. Bertolo, M.F. Abreu, A.P. Del Rio, C.C. Mazon, J.F. Marques-Neto, J.L. Poole, E. Magalhães

P.280 RANDOMIZED FEASIBILITY TRIAL OF THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK HAND EXERCISE PROGRAM (SPIN-HAND)
L. Kwakkenbos, M.E. Carrier, I. Boutron, J. Welling, M. Sauve, C. van den Ende, A.A. Schouffoer, M. Hudson, B.D. Thombs, L. Mouton

P.281 RELATIONSHIP BETWEEN GLYCOPROTEIN YKL-40 AND MUSCULOSKELETAL ULTRASONOGRAPHY (US) IN SYSTEMIC SCLEROSIS (SSC)
R. Karalilova, M. Kazakova, V. Sarafian, M. Matucci-Cerinic, An. Batalov

P.282 FOOT INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A SINGLE-CENTRE REPORT
G. Cuomo, C. Romano, A. Ruta, L.E. Adinolfi

P.283 CORTICOSTEROID-SPARING BENEFIT OF INTRAVENOUS IMMUNOGLOBULINS IN SYSTEMIC SCLEROSIS-ASSOCIATED MYOPATHY: A RETROSPECTIVE STUDY OF 52 PATIENTS

P.284 LACK OF SPECIFICITY OF CLINICAL IMPRESSIONS AND LABORATORY WORK UP FOR DIAGNOSING OSTEOMYELITIS IN SYSTEMIC SCLEROSIS PATIENTS
MUSCULOSKELETAL SYSTEM & REHABILITATION

P.285 PATTERNS OF PHYSICAL THERAPY PRESCRIPTION IN PATIENTS OF THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS

GASTROINTESTINAL/NUTRITION

P.287 THE ASSOCIATION BETWEEN TWO NON-INVASIVE METHODS FOR THE ASSESSMENT OF SEVERITY OF GASTROINTESTINAL INVOLVEMENT AND MALNUTRITION IN SYSTEMIC SCLEROSIS: SELF-REPORTED QUESTIONNAIRES AND CAPILLAROSCOPY

P.288 HIGH-RESOLUTION IMPEDANCE MANOMETRY PATTERNS IN ASYMPTOMATIC SYSTEMIC SCLEROSIS PATIENTS
S. Vettori, D. Capocotta, R. Chieffo, V. Giacco, L. Docimo, S. Tolone

P.289 HEPATOBILIARY INVOLVEMENT (HBI) IN SYSTEMIC SCLEROSIS (SSC): CHARACTERISTICS AND SURVIVAL OF PATIENTS FROM THE SPANISH RESCEL REGISTRY

P.290 GASTROINTESTINAL ENDOSCOPIC FINDINGS IN SYSTEMIC SCLEROSIS
A. Sari, B. Armagan, A. Erden, D. Guven, L. Kilic, A. Akdogan

P.291 CHARACTERISTICS OF THE ESOPHAGEAL INVOLVEMENT AND ITS CORRELATIONS IN A LARGE COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
P. Sampaio-Barros, H. Silva, A. P. Luppino Assad, D. Andrade

P.292 TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW

P.293 NUTRITIONAL STATUS CORRELATES WITH ORAL HEALTH AND DISEASE CHARACTERISTICS IN SYSTEMIC SCLEROSIS PATIENTS - CROSS-SECTIONAL PILOT STUDY
M. Radic, K. Boric, I. Bozic, K. Parat, D. Martinovic Kaliterna

P.294 ASSESSMENT OF ESOPHAGEAL DYSMOTILITY DISORDER BY HIGH RESOLUTION MANOMETRY IN SYSTEMIC SCLEROSIS: ASSOCIATION WITH CLINICAL FEATURES
H. Poormoghim, H. Fakre Yaseri, S. Dodangheh, A. Jalali, E. Andalib

P.295 GASTROINTESTINAL INVOLVEMENT AND MALNUTRITION RISK IN SCLERODERMA PATIENTS
E. Pigatto, G. Bagnato, P. Polito, E. Zanatta, M. Favaro, A. Saitta, L. Punzi, F. Cozzi

P.296 ROLE OF HIGH RESOLUTION MANOMETRY FOR DIAGNOSIS OF ESOPHAGEAL DISORDERS IN A GROUP OF PATIENTS WITH SYSTEMIC SCLEROSIS
V. Parra Izquierdo, S. Bernal Macias, V. Costa, A.M. Leguizamo, F. Avila, A. Hani

P.297 COMPARATIVE ANALYSIS OF ENDOSCOPIC FEATURES OF UPPER GASTROINTESTINAL TRACT IN PATIENTS WITH SYSTEMIC SCLEROSIS VERSUS HEALTHY CONTROL
J.W. Park, J.H. Kim, J.S. Kim, E.B. Lee

P.298 HIGHER BODY MASS INDEX IS RELATED WITH DECREASED SERUM TGF-BETA LEVEL IN SYSTEMIC SCLEROSIS
S.S. Koca, B. Gundogdu, B. Oz, A. Karatas, S. Aydin

P.299 ABNORMAL OESOPHAGEAL MOTILITY IS ASSOCIATED WITH DISEASE SEVERITY AND DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS
GASTROINTESTINAL/NUTRITION

P.300 SKIN INVOLVEMENT AND RAYNUD’S PHENOMENON VARIABILITY IN A MONOCENTRIC COHORT OF PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS ALONE AND IN ASSOCIATION WITH PRIMARY BILIARY CIRRHOSIS (PBC)
F. Girelli, A. Ariani, M. Bruschi, E. Fabbri, L. Gardelli, M. Nizzoli

P.301 PREVALENCE AND ASSOCIATED FACTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH AMONG SYSTEM SCLEROSIS PATIENTS

P.302 VIDEOFLUOROSCOPY SWALLOW STUDY IN PATIENTS WITH SYSTEMIC SCLEROSIS. ORAL, PHARYNGEAL AND ESOPHAGEAL PHASE AND CORRELATION WITH CLINICAL PATTERNS
C. Fischetti, P. Fraticelli, A.M. Pisani, L. Zuliani, A. Ferrarini, S. Barchiesi, G.M. Giuseppetti, A. Gabrielli

P.303 DIGESTIVE AND NUTRITIONAL SURVEY IN SYSTEMIC SCLEROSIS PATIENTS
V. Ernest, B. D’Andrea, C. Mettler, S. Gentile, E. Jouve, M.C. Morin, R. Saglio, A. Benyamine, P. Rossi, D. Godard, B. Granel

P.304 CLINICAL IMPACT OF SELENIUM AND VITAMIN C DEFICIENCY IN SYSTEMIC SCLEROSIS

P.305 CHRONIC INTESTINAL PSEUDO-OBSTRUCTION SYNDROME REVEALING A SCLERODERMA
G. Chalhoub

P.306 NUTRITIONAL STATUS, VITAMIN D LEVELS AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Burlui, A. Cardoneanu, A. Gherasim, M. Graur, E. Rezus

P.307 GASTROINTESTINAL INVOLVEMENT AND ENDOCRINE MANIFESTATIONS IN SYSTEMIC SCLEROSIS. REAL LIFE DATA FROM A REFERRAL CENTER IN NORTHERN GREECE
I. Kostoglou-Athanassiou, T. Banti, M. Gatsiou, P. Athanassiou

PREGNANCY & GENDER RELATED ISSUES

P.308 CHARACTERISTICS OF SYSTEMIC SCLEROSIS IN MEN: A COMPARATIVE STUDY IN A GROUP OF TUNISIAN PATIENTS

RECENT ADVANCES IN THERAPY

P.309 HIT HARD AND EARLY

P.310 VITAMIN D DEFICIENCY CORRELATES WITH ADVANCED ORGAN INVOLVEMENT IN EUROPEAN SYSTEMIC SCLEROSIS PATIENTS
A.C. Trombetta, V. Smith, E. Giotto, M. Ghio, S. Paolino, C. Pizzorni, A. Vanhaecke, B. Ruoaro, M. Patane, A. Sulli, M. Cuto

P.311 EFFECT OF 6 MONTHS THERAPY WITH ILOPROST ON ENHANCED LIVER FIBROSIS (ELF) TEST AND ITS ASSOCIATION WITH DISEASE ACTIVITY AND VASCULAR MANIFESTATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)

P.312 ILOPROST THERAPY IN SYSTEMIC SCLEROSIS: A POSSIBLE ROLE ON DISEASE ACTIVITY CHANGES AND CXCL4 CHEMOKINE SERUM LEVELS

P.313 AUTOLOGOUS FAT GRAFTING IN THE TREATMENT OF PATIENTS WITH SYSTEMIC SCLEROSIS: OUR EXPERIENCE AND FUTURE PERSPECTIVES
A. Spinella, M. Pignatti, F. Lumetti, G. Boscai, M. Colaci, E. Cocchiara, G. De Santis, C. Ferri, D. Giuggioli

P.314 TOPICAL NITROGLYCERIN (NTG) VS MATCHING VEHICLE IN SECONDARY RAYNAUD PHENOMENON (RP) – A DOUBLE-BLIND CROSSOVER STUDY OF SUBJECTIVE AND PHYSIOLOGIC RESPONSES TO CONTROLLED COLD CHALLENGE
Recent Advances in Therapy

P.315 Improvement of Dermal Thickness in Systemic Sclerosis Patients Treated with Endothelin Receptor Antagonist: Long Term Study by High Frequency Ultrasound
B. Ruaro, A. Sulli, C. Pizzorni, S. Paolino, V. Tomatis, E. Alessandri, M. Cutolo

P.316 Therapeutic Effect of MSC-Derived Extracellular Vesicles in Systemic Sclerosis
P. Rozier, M. Maumus, A. Maria, C. Jorgensen, D. Noel, P. Guilpain

P.317 Control of Fibroblast Polarization as Potential New Strategy to Terminate Tissue Fibrosis

P.318 Mesenchymal Stem Cell Function is Affected by Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients
G. Fonteneau, C. Bony, R. Goulabchand, A. Maria, C. Jorgensen, P. Guilpain, D. Noel

P.319 Two Years Follow-Up of an Open-Label Pilot Study of Treatment with RituXimab in Patients with Early Diffuse Cutaneous Systemic Sclerosis

P.314 Pertinence of Mycophenolate Mofetil’s Area Under the Curve and/or Pulmonary Involvement

P.325 The Selective S1P1 Antagonist ACT-334441 Ameliorates Murine Sclerodematous Chronic Graft Versus Host Disease
M. Kano, M. Date, T. Matsushita, Y. Hamaguchi, K. Takehara

P.326 Molecular Mechanism for the Therapeutic Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers of Systemic Sclerosis

P.327 Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
T. Ishii, Y. Kamogawa, H. Fujii, Y. Shirotai, T. Shirai, Y. Fujita

P.328 RituXimab Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease

P.329 Adipose-Derived Cell Therapy for Hand Dysfunction in Patients with Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial

P.330 Novel Machine Learning Classifier Accurately Predicts the Intrinsic Molecular Subsets for Patients with Systemic Sclerosis in Multiple Independent Cohorts
J. Franks, V. Martyanov, G. Cai, M. Whitfield

P.331 Tocilizumab is a Promising Treatment Option for Therapy Resistant Juvenile Localised Scleroderma Patients
I. Foeldvari, J. Anton, M. Friswell, B. Bica, J. De Inocencio, A. Aquilani, N. Helmus

P.332 Tocilizumab for Systemic Sclerosis-Rheumatoid Arthritis Overlap: A Case Series
I.C. Filipescu, L. Damian, I. Felea, M. Deac-Badarina, C. Parmfil, S. Rednic
RECENT ADVANCES IN THERAPY

P.333 WITHDRAWN

P.334 INTRAVENOUS IMMUNOGLOBULINS PREVENTS EXPERIMENTAL FIBROSIS IN A MURINE MODEL OF SYSTEMIC SCLEROSIS

P.335 EFFECT OF SINGLE COURSE OF ILOMEDIN® IN THERAPY OF DIGITAL ULCERS DUE TO SYSTEMIC SCLEROSIS (SSC)
M. Starovoytova, O. Desinova, O. Koneva, O. Ovsyannikova, L. Gorzanova

P.336 INCREASED CXCL10 SERUM LEVELS IN SSC CAN BE CAUSED BY MYOCYTES ACTIVATION AND TARGETED BY SILDENAFIL. A NOVEL THERAPEUTIC OPPORTUNITY FOR PDE5 INHIBITION

P.337 IMATINIB-LOADED GOLD NANO Particles AMELIORATE EXPERIMENTAL LUNG FIBROSIS INDUCED BY BLEOMYCIN
V. Codullo, F. Meloni, S. Breda, S. Inghilleri, E. Cova, C. Montecucco, J. Distler

P.338 ABATAcept IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACy DATA FROM THE EU STAR NETWORK
I. Castellvi, M. Elhai, C. Bruni, P. Airo, L. Beretta, V. Codullo, C. Montecucco, A. Balbir, F. Iannone, M. Matucci-Cerinic, O. Distler, Y. Allanore

P.339 TREATMENT WITH ABATAcept PROTECTS AGAINST EXPERIMENTAL GASTROINTESTINAL TRACT, LUNG PARENCHYMAL AND VESSEL FIBROSIS

P.340 SODIUM THIOSULPHATE IS AN EFFECTIVE TREATMENT FOR DYSTROPHIC CALCIFICATIONS
R. Bech, J. Baumgartner, A. Braae-Olesen

P.341 ENDOVENOUS PROSTANOIDs INFUSIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS MICROANGIOPATHY: COMPARISON BETWEEN TWO THERAPEUTIC REGIMENS
S. Barsotti, S. Bilia, A. D’Ascanio, A. Della Rossa, M. Mosca

P.342 PAN-PPAR AGONIST IVA337 IS EFFECTIVE IN THE PREVENTION OF EXPERIMENTAL LUNG FIBROSIS AND PULMONARY HYPERTENSION

P.343 IS ABATAcept A USEFULL TREATMENT FOR PATIENTS WITH LOCALIZED SCLERODERMA? A CASE DESCRIPTION OF ALL LOCALIZED SCLERODERMA PATIENTS TREATED WITH ABATAcept AT THE DEPARTMENT OF DERMATOLOGY, AARHUS UNIVERSITY HOSPITAL, FROM 2009 TO 2016
S. Wehner Fage, K. Bakke Arvesen, A.B. Olesen

NEW REGISTRIES

P.344 MORTALITY IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT
K. Solanki, C. Ooi, C. Lao, C. Frampton, D.H.N. White

P.345 CLINICAL PATTERN OF SYSTEMIC SCLEROSIS IN EASTERN EUROPEAN REGION
V. Semenov, T. Lysunets, O. Kuryata

P.346 LONG-TERM FOLLOW-UP OF PRIMARY RAYNAUD´S PHENOMENON COHORT OF 214 PATIENTS

P.347 THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT: BASELINE CLINICAL FEATURES AND COMPARISON TO OTHER LARGE SCLERODERMA COHORTs
NEW REGISTRIES

P.348  DIFFUSE SYSTEMIC SCLEROSIS WITH ANTI-CENTROMERE ANTIBODIES AND LIMITED SYSTEMIC SCLEROSIS WITH ANTI-TOPOISOMERASE ANTIBODIES: THINKING BEYOND THE SKIN
N. Iniést Arandía, G. Espinosa Garriga, M. Rodríguez Carballeira, X. Pla Salas, A. Chamorro, I. Perales Fraile, V. Fonollosa Pla, C.P. Simeon Aznar

P.349  STUDY OF THE IMMUNOLOGICAL PROFILE OF PATIENTS SUFFERING FROM PRURITUS IN THE SYSTEMIC SCLERODERMA
G. Gourier, C. Therene, C. Abasq-Thomas, E. Brenaut, H. Sonbol, E. Pasquier, A. Saraux, V. Devauchelle, E. Le Moigne, L. Misery, Y. Renaudineau

P.350  VITAMIN D INHIBITS IL-17A AND IL-17F SECRETION IN PBMC FROM SYSTEMIC SCLEROSIS PATIENTS

P.351  REUMA.PT/SCLERODERMA PROTOCOL: A SINGLE CENTRE EXPERIENCE

P.352  SKIN BIOMECHANICAL PROPERTIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: WHAT PARAMETER SHOULD BE USED?
S. Blaise, M. Roustit, J.L. Cracowski

P.353  PROFILE OF ARAB PATIENTS DIAGNOSED WITH SYSTEMIC SCLEROSIS IN QATAR
F. Alam Fiaz, S. Al Emadi Samar

CASE REPORTS

P.354  CASE SERIES OF MALIGNANCIES IN OUR WAIKATO COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
K. Solanki, J. Schollum, D.H.N. White

P.355  THINK ABOUT SCLERODERMA RENAL CRISIS
P. Smets, L. Olagne, A. Mania, A. Ducornet, A. Aumaitre, M. Andre

P.356  PANSCLEROTIC MORPHEA AND EOSINOPHILIC FASCIITIS; A SPECTRUM OR DISTINCT ENTITIES?
A. Saracino, C. Orteu

P.357  AN INDIVIDUALIZED MANUAL THERAPY TECHNIQUES IN PATIENTS WITH SYSTEMIC SCLEROSIS MAY IMPROVE HAND MOBILITY – CASE REPORT
M.W. Romanowski, W. Romanowski, W. Samborski

P.358  MACITENTAN IN SCLERODERMA RENAL CRISIS MANAGEMENT IN PATIENT WITH RNA POLIMERASE III POSITIVE SYSTEMIC SCLEROSIS AND T-CELL LYMPHOBLASTIC LYMPHOMA
H.S. Park, M. Millan, B. Magallares, P. Moya, C. Diaz-Torne, A. Laiz, I. Castellvi

P.359  WITHDRAWN

P.360  RITUXIMAB IN 2 PATIENTS - SKIN AND MUSCLE INVOLVEMENT
R. Nichitean, A. Mociran, G. Gusetu, S. Rednic

P.361  PEDIATRIC SCLERODERMA CASE ASSOCIATED WITH BOTH PM-SCL-75 AND PM-SCL-100 ANTIBODIES

P.362  SHOULD WE LOOK FOR ANTI-RNA POLYMERASE III ANTIBODIES IN SYSTEMIC SCLEROSIS PATIENTS WITH ANTI-CENTROMERE OR ANTI-TOPOISOMERASE I ANTIBODIES?
R. Muller, A. Benyamine, D. Bertin, X. Heim, A. Aillaud, J.R. Harle, M. Ebbo, N. Schleinitz, G. Kaplanski, C. Gomez, P. Rossi, B. Granel, N. Bardin

P.363  COEXISTENCE OF AORTITIS AND DIFFUSE SYSTEMIC SCLEROSIS - A CASE REPORT
E. Morgiel, M. Madej, B. Maciazek-Chyra, M. Guzinski, A. Czarnecka, P. Wiland
CASE REPORTS

P.364 SEVERE WEIGHT LOSS IN DIFFUSE SYSTEMIC SCLEROSIS: WHAT CAN IT MEAN?

P.365 AUTO-ANTIBODIES PROFILE IN SYSTEMIC SCLERODERMA: CONCERNING 412 PATIENTS

P.366 WERNER SYNDROME IS A SCLERODERMA LIKE SYNDROME

P.367 SUCCESSFUL DELIVERY WITH SPINAL ANESTHESIA FOR CESAREAN SECTION IN A PATIENT WITH DIFFUSE SYSTEMIC SCLEROSIS AND PULMONARY FIBROSIS
M. Kechida, M. Hafsa, R. Mesfar, W. Benyahia, S. Hammami, I. Khochtali

P.368 JUVENILE SYSTEMIC SCLEROSIS REVEALING POLYSPLENIA SYNDROME
M. Kechida, R. Mesfar, B. Hmida, W. Benyahia, R. Klii, S. Hammami, I. Khochtali

P.369 PALISADED NEUTROPHILIC GRANULOMATOUS DERMATITIS IN A PATIENT WITH SYSTEMIC SCLEROSIS-RHEUMATOID ARTHRITIS OVERLAP SYNDROME

P.370 A CASE OF COEXISTENCE OF SYSTEMIC SCLEROSIS AND ANKYLOSING SPONDYLITIS
J. Jun, B. Koo, Y. Song, S. Lee, C. Choi, T. Kim

P.371 BENIGN SPONTANEOUS PNEUMOPERITONEUM DUE TO PNEUMATOSIS CYSTOIDES INTESTINALIS IN A PATIENT WITH MIXED CONNECTIVE TISSUE DISEASE: A CASE REPORT
C. Choi, B. Kang, J. Jun

P.372 SEIZING WOUND CARE IN SCLERODERMA: USE OF TOPICAL PHENYTOIN IN DIFFICULT TO TREAT LEG ULCERS IN SCLERODERMA PATIENT
S. Jain, S. Lakshminarayanan

P.373 IMMUNOSUPPRESSANT THERAPIES FOR A SYSTEMIC SCLEROSIS PATIENT WITH ANTI-CENTRIOLE ANTIBODY
Y. Ishii, H. Fujii, Y. Hoshi, Y. Fujita, T. Shirai, Y. Shirota, T. Ishii, H. Harigae

P.374 SYNCHRONOUS LUNG CANCER OF PROGRESSIVE SYSTEMIC SCLERODERMA!! ABOUT A NEW REPORTED CASE
D. Hakem, M. Boudjema, K. Abacci, N. Slimani, R. Boughrarou, B. Mansouri, S. Haddam, N. Djenane, C. Aimeur, A. Berrah, R. Baba-Ahmad

P.375 SCLERODERMA WITH RENAL CRISIS INITIALLY DIAGNOSED AS RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
K. Gheorghe, A. Nordin

P.376 RITUXIMAB FOR THE TREATMENT OF SYSTEMIC SCLEROSIS-RELATED CARDIOMYOPATHY. CLINICAL CASES
L. Garzanova, L. Ananieva, D. Alekseev, O. Koneva, O. Ovsyannikova, I. Nikishina

P.377 COEXISTENCE OF RARE ENTITIES IN SYSTEMIC SCLEROSIS - COINCIDENCE OR RELATIONSHIP?
R. Ferreira, S. Pimenta, N. Melo, L. Costa

P.378 CAPILLAROSCOPY IN SSC/DM
Z. Fabianne

P.379 IMMUNOADSORPTION IN REFRACTORY, SEVERE SYSTEMIC SCLEROSIS
A. Erler, J. Fantana, A. Kleymann, N. Leuchten, K. Conrad, M. Aringer

P.380 PROGRESSIVE SYSTEMIC SCLEROSIS WITH CONCOMITANTLY OCCURRING ARTERIAL STIFFNESS: A CASE REPORT
A. Eman Abdulle, S.C van de Zande, A.M. van Roon, D.J. Mulder

P.381 INTRAVENOUS EPOPROSTENOL - A PROMISING THERAPY IN SCLERODERMA DIGITAL VASCULOPATHY
A.C. Duarte, M.J. Loureiro, M.J. Santos, A. Cordeiro

P.382 NINTEDANIB – A NEW OPPORTUNITY FOR SYSTEMIC SCLEROSIS PATIENTS?
A.C. Duarte, M.J. Santos, A. Cordeiro

P.383 CHRONIC COMPARTMENT SYNDROME IN LOCALISED SCLERODERMA
D. Dan, P. Zufferey, G. Gremion

P.384 ROLE OF RITUXIMAB IN SEVERE HEALING DIGITAL ULCER AND GANGRENE
S.H. Chang, S.W. Lee

P.385 DEVELOPMENT OF SYSTEMIC SCLEROSIS IN TRANSGENDERED FEMALES: A CASE SERIES
C. Campochiaro, L.V. Host, V.H. Ong, C.P. Denton
CASE REPORTS

P.386  PARANEOPLASTIC SYSTEMIC SCLEROSIS ASSOCIATED WITH OVARIAN CARCINOMA
H. Bugaut, C. Robert

P.387  SYSTEMIC SCLEROSIS ASSOCIATED WITH NEUTROPHILIC DERMATOSES: A REPORT OF TWO CASES

P.388  SUCCESSFUL LONG-TERM TREATMENT OF SYSTEMIC SCLEROSIS PATIENTS WITH D-PENICILLAMINE
M. Baresic, D. Bosnic, M. Sentic, B. Anic

P.389  RITUXIMAB TREATMENT IN SYSTEMIC SCLEROSIS. REPORT OF TWO CASES
P. Athanassiou, T. Banti, M. Gatsiou
GENERAL INFORMATION

CONGRESS VENUE
Bordeaux Convention Centre
Avenue Jean-Gabriel Domergue
33000 Bordeaux, France

HOW TO GET TO THE CONGRESS CENTER
By car
EXIT N° 4A - 4B Parc des Expositions to Bordeaux Lac
Free car park nearby
From train station Gare St Jean: 20 minutes
From airport: 20 min

By train
Arrival SAINT JEAN Train Station,
Go the Tramway line C
Stop: Palais des Congrès (40 min)

By plane
Take Bus Shuttle to downtown, then tramway line C

ORGANIZING SECRETARIAT
AIM Group International - Florence Office
Viale G. Mazzini, 70 - 50132 Florence, Italy
Tel. +39 055 233881 - Fax +39 055 2480246
ssc2018@aimgroup.eu

Onsite the registration desk will be open for participants at the following times:
Thursday, February 15 from 11:30 to 20:00,
Friday, February 16 from 07:30 to 19:00
Saturday, February 17 from 07:30 to 18:00

REGISTRATION FEES
(VAT 20% included)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
<th>Late fee and onsite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>€830.00</td>
<td></td>
</tr>
<tr>
<td>Young Investigators/Fellows *</td>
<td>€365.00</td>
<td></td>
</tr>
<tr>
<td>Phd Basic Scientists**</td>
<td>€365.00</td>
<td></td>
</tr>
<tr>
<td>HP (Nurses and Physiotherapists)</td>
<td>€365.00</td>
<td></td>
</tr>
<tr>
<td>Medical Students***</td>
<td>€240.00</td>
<td></td>
</tr>
</tbody>
</table>

* For young doctors under 35 years of age.
** Copy of the ID or passport is requested.
*** These individuals must include a letter from their program director, chief of service or faculty advisor to be eligible for reduced fees.

Registration fees include:
Congress kit, access to the scientific sessions, admission to the exhibition and poster area, certificate of attendance, coffee breaks and working lunches as indicated in the programme, abstracts book and online subscription for two years to “Journal of Scleroderma and Related Disorders”.

Registration fee for patients includes:
Congress kit, access to the Opening Ceremony of the medical congress, scientific sessions of the patient congress only, coffee breaks and working lunch as indicated in the patient programme. Patient registrations are not entitled to attend the medical congress.

CONGRESS BADGES
Each participant may collect the badge at the registration desk. Participants are kindly requested to wear their badge during all congress activities and social events.

INTERNET CONNECTION
Free wi-fi connection is available in all congress spaces.
Wifi: SSC2018
Password: SSC2018

LANGUAGE
The official language is English.

CATERING
Coffee breaks
Coffee breaks will be organized in the exhibition area, during the following times:
Friday, February 16 from 10:30 to 11:00 and from 17:25 to 17:50, Saturday, February 17 from 10:10 to 10:40.

Lunches
A standing buffet lunch will be offered to all registered participants on Friday, February 16 from 13:40 to 14:40 and on Saturday, February 17 from 13:15 to 14:20 in the exhibition area.
CERTIFICATE OF ATTENDANCE
Certificates of attendance will be sent by email on Tuesday, February 20.

EXHIBITION
An exhibition will be open in the following days:
Thursday, February 15 from 15:00 to 19:30,
Friday, February 16 from 08:00 to 18:30,
Saturday, February 17 from 08:00 to 14:30.

SOCIAL PROGRAMME
Welcome Cocktail - Thursday, February 15
A welcome cocktail will be held after the Opening Lectures in the hall of the congress center for all registered participants and patients.

Congress Dinner - Friday, February 17
The seated Congress Dinner with buffet service will be held at “Chateau Giscours”, 10 Route de Giscours - Labarde. Transfer by bus will be provided from Hotel Pullman Lac (in front of the congress center) at 20:00. Remaining tickets will be sold at the “New registration” desk until Friday, February 16 at 10:00.

SCIENTIFIC INFORMATION
Abstract sessions
Selected papers will be orally presented by the Authors. Authors have the time indicated in the programme including the discussion.

Poster session
See information at page 22

Meet the Professor sessions
Meet the Professor sessions will be organized on Friday, February 16 from 08:00 to 09:00 (see the scientific program - page 6) for young practicing physicians only, for a maximum of 20 participants each, on first come, first served basis. Remaining places can be booked at the “New registration” desk.

Speaker Preview Room
Speakers are kindly requested to load their presentation slides in the Speaker Preview Room at least three hours before their presentation (or, if their session starts at 8:00, the previous day). The opening hours of the Speaker Preview Room are:
Thursday, February 15 from 11:30 to 19:00,
Friday, February 16 from 07:30 to 18:30
Saturday, February 17 from 07:30 to 17:00.

The following facilities will be provided in the Speaker Preview Room:
• computers (operating system Windows and MAC) to review, alter and upload the presentations to the server
• support by technical staff is available
The technicians will transfer the presentation to the corresponding Session Room. All speakers will easily find their presentations directly in the meeting room.

Abstract book
The abstracts of the oral presentations and posters are included in the Journal of Scleroderma and Related Disorders in the congress bag.
2018 Update on Pulmonary Arterial Hypertension – Connective Tissue Disease

Saturday, 17 February 2018
12:15 – 13:15

Chair: Dinesh Khanna (USA)

Bordeaux Convention Centre
Auditorium A
Bordeaux, France

AGENDA

12:15 – 12:20  Welcome and Opening Remarks  Dinesh Khanna

12:20 – 12:45  What’s New in SSc?
- EUSTAR Predictors of dcSSc
- Current EULAR Recommendations  Oliver Distler

12:45 – 12:55  Screening for and Diagnosing PAH in Systemic Sclerosis Patients  Hossein Ardeschir Ghofrani

12:55 – 13:05  sGC Stimulation in PAH-CTD Patients: Results From the Pivotal PATENT Study  Marc Humbert

13:05 – 13:15  Round Table and Q&A  Dinesh Khanna

13:15  Summary and Close  Dinesh Khanna
ACKNOWLEDGEMENTS
The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

PLATINUM SPONSORS

ACTELION
A JANSSEN PHARMACEUTICAL COMPANY
OF Johnson & Johnson

Boehringer Ingelheim

GOLD SPONSORS

CORBUS PHARMACEUTICALS

gsk

MSD

INVENTING FOR LI

SILVER SPONSORS

Roche

ITALFARMACO

BRONZE SPONSOR

BAYER
# Timely and effective decisions in PAH-SSc

**Co-Chairs**

Yannick Allanore, Marco Matucci-Cerinic

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:05 – 12:10</td>
<td>Introduction</td>
<td>Yannick Allanore</td>
</tr>
<tr>
<td>12:10 – 12:30</td>
<td>Identification and treatment of PAH-SSc patients at an early disease stage</td>
<td>Dinesh Khanna</td>
</tr>
<tr>
<td>12:30 – 12:50</td>
<td>Utilization of risk assessment for the management of patients</td>
<td>Athénaïs Boucly</td>
</tr>
<tr>
<td>12:50 – 13:10</td>
<td>Double oral combination – The way forward for all PAH-SSc patients?</td>
<td>Daniel Dumitrescu</td>
</tr>
<tr>
<td>13:10 – 13:30</td>
<td>The role of the prostacyclin pathway in the treatment of PAH-SSc</td>
<td>Kristin B. Highland</td>
</tr>
<tr>
<td>13:30 – 13:40</td>
<td>Panel discussion</td>
<td>Marco Matucci-Cerinic</td>
</tr>
</tbody>
</table>

---

**Actelion Satellite Symposium**

5th Systemic Sclerosis World Congress 2018
Bordeaux, France

Visit the ACTELION BOOTH NO. 13
to learn more about PAH & download the symposium key slides